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1 Introduction 
Obesity is a major health problem in equines. Obesity leads to insulin dysregulation and a 
predisposition towards laminitis, which are key components of the equine metabolic syndrome 
(EMS; DURHAM et al. 2019). It is well established that human obesity is accompanied by 
hepatic lipid alterations, termed Non-Alcoholic Fatty Liver Disease (NAFLD; TINIAKOS et 
al. 2010). In contrast to that, data are missing whether equine obesity affects the hepatic 
metabolism as well. Various parameters have been implemented to evaluate hepatic metabolism 
in obese humans. Non-invasive parameters include assessing serum liver enzyme activities and 
bile acids (BA), which have been associated with body mass index (BMI) and obesity related 
metabolic disturbances, such as insulin resistance (ALI et al. 2006, LIU et al. 2014a, MA and 
PATTI 2014). Definitive diagnosis of NAFLD is made by light microscopy of liver biopsies 
(BEDOSSA 2016). Determination of hepatic enzymes mediating fatty acid influx, such as 
lipoprotein lipase (LPL), provide further information about hepatic lipid metabolism 
(PARDINA et al. 2009). Hepatic accumulation of lipids induces hepatocellular inflammation 
with subsequent production of pro-inflammatory cytokines (CAI et al. 2005). Several studies 
have detected associations of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor 
necrosis factor α (TNFα), with obesity, insulin resistance and NAFLD (BLÜHER et al. 2005, 
HAUKELAND et al. 2006, KROGH-MADSEN et al. 2006, MANCO et al. 2007). In contrast 
to human obesity research, the effects of equine obesity with its associated consequences on 
hepatic alterations have been only addressed in limited studies. For example, CHAMEROY et 
al. (2011) reported serum liver enzyme activities exceeding the reference ranges in horses with 
a history of laminitis. The authors suggested hepatic steatosis as causative factor, but hepatic 
lipid accumulation in examined equines was not investigated. In addition to the association of 
obesity with hepatic inflammation, it was shown that human obesity correlates with systemic 
low-grade inflammation and with higher levels of oxidative stress (D'ARCHIVIO et al. 2012, 
ESSER et al. 2014). Human obesity research also has investigated circulating concentrations of 
anti-inflammatory and antioxidant factors, such as vitamin E (α-tocopherol) and vitamin A 
(retinol). Serum concentrations of both vitamins were often shown to be decreased in conditions 
of obesity (BOTELLA-CARRETERO et al. 2010, PEREIRA et al. 2012). The influence of 
equine obesity on serum concentrations of α-tocopherol and retinol has not been evaluated yet. 
We hypothesized that body weight (BW) gain would alter hepatic metabolism of equines, with 
elevation of serum liver enzyme activities, BA, hepatic lipid content and hepatic inflammatory 
parameters. Additionally, we hypothesized that serum α-tocopherol and retinol concentrations 
would decrease with increasing BW. Finally, it was hypothesized that obesity leads to more 
profound hepatic changes in ponies compared to horses, as ponies are more prone to obesity 
associated metabolic diseases such as laminitis. 
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2 Literature 
 
2.1 Equine obesity 
Obesity is defined as the accumulation of excessive adipose tissue (GERMAN 2006). As in 
human obesity, equines become obese in conditions of excess energy intake and little physical 
exercise. Furthermore, domestic conditions prevent the natural cycle of weight loss during 
winter that occur under natural circumstances (DUGDALE et al. 2011). These considerations 
may explain the high prevalence of overweight and obese horses throughout the world (24.5-
45%; WYSE et al. 2008, THATCHER et al. 2008, ROBIN et al. 2015, POTTER et al. 2016). 
Robust pony breeds, which are adapted to rough environmental conditions, are theorized to 
have developed a predisposition to insulin resistance as survival advantage in terms of famine 
by elevating the storage of triglycerides in adipose tissue (JEFFCOTT et al. 1986). These so-
called “easy keepers” are highly predisposed to obesity and its consequences under the 
circumstances of continuous supply of feed. 
The body condition score (BCS) system is a useful tool to assess the general body condition of 
horses and ponies. The scoring system of CARROLL and HUNTINGTON (1988) evaluates the 
shape of the neck, the back and ribs and of the pelvis on a scale from 0 to 5. Zero score points 
indicate emaciation and 5 score points represent an obese body condition. Horse owners often 
underestimate the body condition of their equines (POTTER et al. 2016). Regional adiposity in 
equines, especially at the neck is suspected to be correlated with an increased risk for insulin 
resistance (FRANK et al. 2006). Therefore, the cresty neck score (CNS) was developed by 
CARTER et al. (2009a). The CNS evaluates the regional adiposity on a scale from 0 to 5, with 
0 score points representing no palpable crest fat and 5 score points indicating a fatty crest that 
droops to one side. 
 
2.1.1 Insulin dysregulation 
Generalized obesity and/or regional adiposity are often accompanied by insulin dysregulation 
in equines. According to FRANK and TADROS (2014), insulin dysregulation includes 
excessive insulin responses to oral sugars, fasting hyperinsulinemia and insulin resistance. The 
latter defines the failure of insulin-sensitive tissues to respond to insulin. Obesity is linked to 
insulin resistance by two fundamental theories: (1) adipokines and cytokines are released from 
adipose tissue and downregulate signaling pathways of insulin and (2) storage of intracellular 
lipids in tissues other than adipose tissue such as the liver (D'ADAMO et al. 2010, TADROS 
and FRANK 2013). Equine studies have confirmed the strong relation of obesity to insulin 
dysregulation. CARTER et al. (2009b) found a 71% decrease in insulin sensitivity in adult 
Literature 
 
3 
 
geldings after BW increased by 20%. The importance of insulin for metabolic diseases was 
further highlighted by studies of ASPLIN et al. (2007) and LAAT et al. (2010), who reported 
the induction of laminitis by insulin infusion in healthy ponies and horses. GEOR et al. (2013) 
stated that pony breeds generally have lower insulin sensitivity and a higher prevalence of 
hyperinsulinemia in comparison to horses. 
Diagnostic tools to detect insulin dysregulation include basal measurements of blood glucose 
and insulin concentrations and dynamic test protocols. Hyperinsulinemia has been stated to be 
identified by a fasting serum insulin concentration above 20 µU/mL (FRANK 2009). To obtain 
a more accurate impression of insulin metabolism, dynamic test protocols are preferable. For 
example, the combined glucose-insulin test (CGIT) developed by EILER et al. (2005) allows a 
more detailed insight into the glycemic and insulinemic responses of equines. After IV 
administration of 150 mg/kg BW glucose immediately followed by 0.1 U/kg BW fast acting 
insulin, blood samples are collected at 0, 1, 5, 15, 25, 35, 45, 60, 75, 90, 105, 120, 135, and 150 
minutes after the insulin application. Equines are classified as insulin resistant if the plasma 
glucose concentrations are above baseline at 45 minutes post injection. Serum insulin 
concentrations above 100 µU/mL at 45 minutes post injection also were considered to indicate 
insulin resistance. According to FRANK (2009), elevated insulin concentrations to a 
standardized glucose challenge indicate that increased pancreatic insulin secretion is necessary 
to compensate for the insulin resistance or that insulin clearance is compromised. 
 
2.1.2 Obesity associated consequences 
Endocrinopathic laminitis is the most detrimental consequence of obesity and insulin 
dysregulation. While the prevalence of endocrinopathic laminitis is not well established, reports 
of overall laminitis frequency in the equine population have varied from as little as 1.5% to 
34% (WYLIE et al. 2011). However, in an equine referral hospital, 89% of all laminitis cases 
in a 16-month period had underlying endocrinopathies (KARIKOSKI et al. 2011). One third of 
the horses suffering from endocrinopathic laminitis were diagnosed with Pituitary Pars 
Intermedia Dysfunction. Two thirds of the laminitic horses showed basal hyperinsulinemia and, 
95% of the hyperinsulinemic equines were obese (KARIKOSKI et al. 2011). FRANK et al. 
(2010) hypothesized that, based on recent research, laminitis may be linked to 
hyperinsulinemia, insulin resistance and obesity by various mechanisms such as endothelial cell 
dysfunction within blood vessels of the hoof (JANSSON 2007), digital vasoconstriction 
(SARAFIDIS and BAKRIS 2007), impaired glucose uptake by epidermal cells (FRENCH and 
POLLITT 2004), altered epidermal cell function or mitosis (NOURIAN et al. 2007) and matrix 
metalloproteinase activation by glucose deprivation or reactive oxygen species (FRENCH and 
POLLITT 2004). TREIBER et al. (2006) described a prelaminitic metabolic syndrome and was 
able to predict the occurrence of laminitis in ponies based on body condition, plasma 
triglyceride concentration and proxies for insulin sensitivity and pancreatic β-cell response. 
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This highlights the strong interrelations between obesity, insulin dysregulation and laminitis. It 
has to be noted, that obesity does not necessarily lead to insulin resistance or laminitis and 
furthermore, insulin resistance and laminitis can occur in lean animals as well (BAILEY et al. 
2008, GEOR et al. 2013). 
 
2.1.3 Equine metabolic syndrome 
The International Diabetes Federation proposed in 2006 a worldwide diagnostic tool for the 
human metabolic syndrome (metS). Based on this, metS is characterized by the presence of 
obesity, increased serum triglyceride concentrations, reduced serum high density lipoprotein–
cholesterol concentrations, increased blood pressure and increased fasting plasma glucose 
concentrations (ALBERTI et al. 2006). EMS may be comparable to metS in humans. Obesity, 
insulin dysregulation and a predisposition towards laminitis constitute the three key 
components of EMS. Dyslipidemia, hyperleptinemia, arterial hypertension and low-grade 
inflammation are further possible components of EMS (FRANK et al. 2010, DURHAM et al. 
2019). Pony breeds seem to be more susceptible to EMS than most horse breeds (JOHNSON 
et al. 2010). 
 
2.2 Liver metabolism in equine obesity 
The liver has a central role in several metabolic processes, e.g. processing absorbed nutrients, 
detoxification for example of ammonia, synthesis of coagulation factors and BA (GEHLEN et 
al. 2010). Hepatocytes constitute 70% of the cells located in the liver and the resident 
macrophages of the liver are named Kupffer cells (SALOMON and ACHILLES 2008). 
 
2.2.1 Non-Alcoholic Fatty Liver Disease 
Lipid infiltration of hepatocytes occurs in various species. For example, obese horses in 
negative energy balance undergo a fat mobilization, which leads to hyperlipemia and hepatic 
lipidosis (GEHLEN et al. 2010). In human medicine, hepatic steatosis in the absence of 
significant alcohol abuse or other known liver diseases is termed Non-Alcoholic Fatty Liver 
Disease (NAFLD). This disease is frequently associated with obesity (ADAMS et al. 2005) and 
represents the most common liver disease in developed countries, with a prevalence of up to 
30% (BROWNING et al. 2004). Clinical signs range from simple steatosis to steatohepatitis, 
advanced fibrosis and, rarely, cirrhosis (PASCHOS and PALETAS 2009). The diagnostic basis 
of NAFLD is that more than 5% of hepatocytes contain lipid droplets as evaluated by light 
microscopy of liver samples (BEDOSSA 2016). In general, steatosis results from a 
dysregulation of fatty acid influx to the liver, fatty acid efflux, and hepatic de novo lipogenesis 
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(KOPPE 2014). Although the pathogenesis of NAFLD is not completely understood, insulin 
resistance accompanying obesity seems to be a crucial factor. Insulin resistance leads to an 
impaired inhibition of lipolysis in all adipose tissues. Together with obesity this mechanism 
results in elevated circulating levels of free fatty acids (KOPPE 2014) and contributes to 
steatosis as 60-80% of hepatic stored lipids originate from circulating free fatty acids 
(PASCHOS and PALETAS 2009). 
In contrast to the effort in human medicine, hepatic alterations in equine obesity have not been 
as intensively investigated yet. Serum gamma-glutamyl transferase (GGT) and aspartate 
aminotransferase (AST) activities were reported to exceed the reference ranges in obese horses 
with a history of laminitis (CHAMEROY et al. 2011). The authors suggested that equine obesity 
was a possible contributing factor to the altered laboratory parameters in hepatic lipidosis. 
Furthermore, the toll-like receptor pathway, which is important in coordinating the innate 
immunity, was activated in liver tissue of horses suffering from laminitis and obesity (STOKES 
et al. 2010). 
 
2.2.1.1 Liver enzyme activities and bile acids 
Diagnosis of NALFD by light microscopy needs biopsy specimens of the liver and is therefore 
invasive and coupled to risks caused by the sampling procedure. Hence, great effort was done 
to implement non-invasive parameters for risk assessment or diagnosis of NAFLD. In addition 
to that, NAFLD constitutes the most common cause for otherwise unexplained elevated 
aminotransferases (CLARK et al. 2003). That led to a new focus of NALFD research, the liver 
enzyme activities and bile acids. 
 
2.2.1.1.1 Alkaline phosphatase  
Alkaline phosphatase is located in several tissues, including liver, bones, intestine, placenta and 
macrophages. It is therefore not a very specific indicator for liver diseases but it is a sensitive 
marker for cholestasis (PEARSON 1999). It is further proven that ALP is additionally expressed 
in several adipose tissue depots where it might function as modulator of adipogenesis (ALI et 
al. 2014). It had been shown in African volunteers that serum ALP levels were higher in obese 
than in lean individuals. The authors suggested the overall fat mass as origin of the majority of 
the ALP measured in the serum (ALI et al. 2006). 
In young equines elevated serum ALP values correlated with physiological high bone turnover 
(GEHLEN et al. 2010). High serum ALP activities in combination with other elevated serum 
liver enzyme activities have been reported in equines with hepatopathies, such as liver neoplasia 
(GEHLEN et al. 2010). To the author´s knowledge, there have been no equine studies 
investigating associations of serum ALP activities and obesity. 
Literature 
 
6 
 
2.2.1.1.2 Aspartate aminotransferase 
Aspartate aminotransferase is present in all tissues except bones, with highest concentrations in 
liver and skeletal muscle (SUCKOW et al. 2012). Equivocal results exist about the association 
of serum AST activities and NAFLD. On one hand, serum AST activities were reported to be 
significantly increased in humans with moderate NAFLD compared to humans without NAFLD 
(WASADA et al. 2008). A recently published study reported an association of fatty liver and 
deregulated hepatic expression of AST and elevated serum AST activities (SOOKOIAN et al. 
2016). Elevated serum AST activities were positively associated with the prevalence of metS 
in the Chinese population (CHEN et al. 2016). On the other hand, CORDEIRO et al. (2015) 
reported serum AST activities within the reference range in human subjects with different 
stages of NAFLD. The evaluation of serum AST activities is suspected to have a low sensitivity 
for NALFD, as only 50% of NAFLD patients show elevated serum AST activities (DIETRICH 
and HELLERBRAND 2014). Other studies reported similar serum AST activities between 
human cohorts with different BMI (KHAN et al. 2015, KÄLSCH et al. 2015). These opposing 
results might be attributable to the nearly ubiquitous occurrence of AST. Hence, the suitability 
of AST as biomarker for NAFLD and metS still needs to be verified. 
DURHAM et al. (2003) described increased serum AST activities as good diagnostic marker 
for liver diseases in horses, but only in combination with other serum liver enzyme activities. 
Six out of 14 obese horses with a history of laminitis were reported to have plasma AST 
activities exceeding reference ranges (CHAMEROY et al. 2011). 
 
2.2.1.1.3 Glutamate dehydrogenase 
Glutamate dehydrogenase (GLDH) is a liver-specific key enzyme in amino acid oxidation and 
urea production. It is mainly present in the mitochondria of the centrolobular hepatocytes 
(SCHMIDT and SCHMIDT 1988, O'BRIEN et al. 2002). Serum GLDH activities were 
significantly increased in cases of a fatty liver syndrome in post mortem examined cows 
(BOGIN et al. 1988). 
Serum GLDH activities are expected to increase in horses with even mild hepatocyte injury 
(DIVERS 2015). Furthermore, WEST (1996) reported elevated plasma GLDH activities in 
horses suffering from lipidosis, of which approximately 50% were obese. 
 
2.2.1.1.4 Gamma-glutamyl transferase 
Gamma-glutamyl transferase is mainly located in epithelial cells in the kidney, pancreas and 
the liver. Notably, high serum activities of GGT are linked with cholestasis in humans 
(WHITFIELD 2001). Additionally, serum GGT activities were correlated with metabolic 
features such as BMI, serum triglycerides and serum insulin concentrations in healthy adults 
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(LIU et al. 2014a). It was also suggested to include increased serum GGT activities as criterion 
for metS, as it may improve the predictive accuracy for cardiovascular diseases (DEVERS et 
al. 2008). 
Plasma GGT activities were reported to exceed the reference range in 9 out of 14 obese horses 
with a history of laminitis (CHAMEROY et al. 2011). The authors speculated hepatic lipidosis 
as causative factor. The confirmation of the occurrence of hepatic lipidosis in individuals 
suffering from laminitis is lacking. WEST (1996) reported that horses admitted to a clinic with 
a purported diagnosis of lipidosis had elevated plasma GGT activities compared to clinically 
healthy horses. Furthermore, EMS ponies had significantly higher serum GGT activities 
compared to healthy control ponies. Unfortunately, differences of body condition between the 
EMS and the control group have not been reported (EL-SHERIF et al. 2014). 
 
2.2.1.1.5 Bile Acids 
Cholesterol, phosphatidylcholine and bilirubin constitute together with BA the components of 
the bile. Bile acids mediate the absorption of dietary fat and fat-soluble vitamins (MA and 
PATTI 2014). Elevated serum BA concentrations can originate from blockage of the bile flow, 
hepatocellular damage or shunts from the portal system to the vena cava (PEARSON 1999). 
Recently, BA have emerged as important modulators of glucose and lipid homeostasis in 
humans (MA and PATTI 2014). Additionally, modulation of circulating BA levels, using BA 
binding factors or receptor agonists, can affect glycemic control, BW and insulin sensitivity 
(MA and PATTI 2014). Serum BA levels were linked with disease severity of NAFLD 
(BECHMANN et al. 2013). Therefore, serum BA are a sensitive marker of liver diseases and, 
moreover, an important marker of metS and NAFLD. 
Serum bile acids are also sensitive markers for dysfunctions of the equine liver. A healthy liver 
removes approximately 90% of BA from the enterohepatic circulation. In case of a 
dysfunctional liver, the circulating BA increase (GEHLEN et al. 2010). Investigations focusing 
BA in equine obesity with its possible consequences are missing. 
 
2.2.2 Obesity related inflammation 
Human obesity has been associated with high circulating levels of pro-inflammatory cytokines 
(e.g., TNFα, interleukin-1 (IL-1), and IL-6) and adipokines (e.g., chemerin; VOZAROVA et al. 
2001, COTTAM et al. 2004, BOZAOGLU et al. 2007). However, equine obesity research has 
provided contradictory data. VICK et al. (2007),  CARTER et al. (2009c) and SUAGEE et al. 
(2011b) all reported inflammatory correlations with obesity. Whereas other studies did not find 
any signs of inflammation in equines suffering from obesity or its detrimental consequences 
(SUAGEE et al. 2011a, HOLBROOK et al. 2012, BAMFORD et al. 2016). Therefore, the 
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interrelations of inflammation and equine obesity with its consequences need further 
elucidation. 
Adipose tissue is known to contribute to chronic inflammation by secreting pro-inflammatory 
cytokines and adipokines in obese humans (SUGANAMI and OGAWA 2010). Adipokines 
such as leptin, adiponectin, resistin or vaspin are biological active substances that are secreted 
by adipose tissue into the circulation and act on both, local and distant tissues (BLÜHER 2012). 
Kupffer cells, the resident liver macrophages, once activated, perform several reactions such as 
initiating a biochemical attack, phagocytosis or enhancing interactions with hepatocytes by 
potentiating the release of a variety of biologically active mediators (for example cytokines, 
chemokines, eicosanoids; BAFFY 2009). Therefore, the liver also might contribute to the 
chronic inflammation associated with obesity. The importance of Kupffer cells was highlighted 
by HUANG et al. (2010), who showed that the depletion of Kupffer cells protects the liver 
against the development of diet induced steatosis and hepatic insulin resistance. According to 
BAFFY (2009), the biological activity of Kupffer cells might be modulated by an altered 
abundance and composition of liver tissue lipids within steatosis by various effects. The ability 
of lipids to adversely affect body tissues is termed lipotoxicity. Steatosis leads to subacute 
hepatocellular inflammation in mice and the induced pro-inflammatory cytokines mediate 
hepatic and systemic insulin resistance (CAI et al. 2005). Hepatic insulin resistance leads to a 
disrupted inhibition of glucose and very-low-density lipoprotein production which induces 
hyperglycemia, compensatory hyperinsulinemia and hypertriglyceridemia in humans (YKI-
JÄRVINEN 2010). 
In insulin resistant and insulin sensitive horses with varying body conditions, messenger 
ribonucleic acid (mRNA) levels of pro-inflammatory cytokines have been investigated in 
different adipose tissue depots but not in the liver (BURNS et al. 2010, BRUYNSTEEN et al. 
2013). 
 
2.2.2.1 Nuclear factor-κB 
Nuclear factor-κB (NF-κB) is a transcription factor for several inflammatory and immune 
related genes, and contributes to the production of pro-inflammatory cytokines, chemokines, 
inflammatory enzymes and adhesion molecules. NF-κB is a key factor for host defense and 
chronic inflammatory diseases (BARNES 1997). Expression of NF-κB in rodent livers was 
activated in two models of obesity in mice, high fat diet and genetically regulated hyperphagia. 
Hepatocellular activation of NF-κB in mice induced hepatic expression of IL-6 which mediates 
hepatic and systemic insulin resistance (CAI et al. 2005). 
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2.2.2.2 Interleukin-1β 
One of the major pro-inflammatory cytokines is IL-1β, that impairs insulin signaling pathways 
(FÈVE and BASTARD 2009). Hepatic triglyceride storage is promoted by Kupffer cells via 
IL-1β dependent suppression of peroxisome proliferator-activated receptor α activity which 
leads to decreased fat oxidation (STIENSTRA et al. 2010). IL-1β was further highlighted as 
important mediator in the transformation from NAFLD in humans to more severe stages, 
namely steatohepatitis (KAMARI et al. 2011). 
In horses blood mRNA expression of IL-1 was positively associated with BCS and percent 
body fat and negatively associated with insulin sensitivity (VICK et al. 2007). The expression 
of IL-1β is altered in digital laminae and lungs of horses with experimentally induced laminitis 
(BELKNAP et al. 2007, STEWART et al. 2009). However, in other studies, mRNA levels of 
IL-1β together with mRNA levels of TNFα and IL-6 of different adipose tissue depots were not 
different between insulin resistant and insulin sensitive horses (BURNS et al. 2010). 
 
2.2.2.3 Interleukin-6 
The cytokine IL-6 has a broad range of biological activities in immune regulation, 
hematopoiesis, inflammation and oncogenesis (KISHIMOTO 2010). High circulating IL-6 
concentrations are associated with obesity, insulin resistance and impaired glucose metabolism 
in humans (BLÜHER et al. 2005). Additionally, serum IL-6 levels are elevated in patients 
suffering from NAFLD, supporting the link of NALFD with low-grade systemic inflammation 
and the strong association of metS and NAFLD (HAUKELAND et al. 2006). This cytokine is 
also known to induce hepatic insulin resistance in mice (KLOVER et al. 2003), probably due 
to the induction of suppressors of cytokine signaling which inhibits the insulin receptor signal 
transduction (SENN et al. 2003). Other studies have provided evidence for an ambivalent role 
of IL-6 in obesity associated liver diseases. For example, YAMAGUCHI et al. (2010) 
postulated that hepatic IL-6 signaling inhibited the progression of hepatic steatosis but enhanced 
liver inflammation in mice. 
Equivocal results about IL-6 also have been reported in horses. VICK et al. (2007) reported that 
blood IL-6 expression decreased with increasing degree of obesity in younger mares. In another 
study, the IL-6 gene expression of peripheral blood cells was significantly decreased in obese, 
hyperinsulinemic horses in comparison to normal weight, normoinsulinemic horses 
(HOLBROOK et al. 2012). On the contrary, ponies suffering from EMS showed significantly 
higher serum IL-6 levels compared to obese ponies without EMS (BASINSKA et al. 2015). 
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2.2.2.4 Tumor necrosis factor α 
The cytokine TNFα is a frequently investigated pro-inflammatory substance that is secreted by 
various cell types, but mainly macrophages and lymphocytes (ANTUNA-PUENTE et al. 2008). 
Hepatic TNFα levels are directly influenced by hepatocytes and Kupffer cells and indirectly by 
the abdominal adipose tissue in humans (CRESPO et al. 2001). Adipose tissue is likely to be a 
major contributor to the elevated serum TNFα concentrations reported in obese humans 
(WINKLER et al. 2003). This cytokine has key roles in insulin resistance and NAFLD. For 
example, TNFα has been reported to: (1) suppress the expression of the glucose transporter type 
4 (GLUT 4); (2) increase serum and intrahepatic free fatty acids by inducing lipolysis; (3) 
trigger insulin resistance by serine phosphorylation of insulin receptor substrate 1 and 2 
(POLYZOS et al. 2009). KROGH-MADSEN et al. (2006) showed that the infusion of TNFα 
induces insulin resistance in healthy humans. Serum TNFα levels were also reported to correlate 
positively with disease severity of NAFLD in children (MANCO et al. 2007). 
In equine research, the link between TNFα and EMS has been reported in several studies. Blood 
mRNA expression of TNFα was positively linked to BCS in 60 mares with differing body 
conditions (VICK et al. 2007). Plasma concentrations of TNFα were significantly higher in 
ponies previously suffering from pasture associated laminitis compared to ponies without a 
history of laminitis maintained under the same management conditions (TREIBER et al. 2009). 
In addition to elevated circulating plasma TNFα in laminitic equines, different experimental 
models of laminitis (carbohydrate overload and black walnut extract administration) were 
reported to increase the hepatic mRNA levels of TNFα in horses (STEWART et al. 2009, 
TADROS et al. 2012). Additionally, ponies suffering from EMS had higher serum 
concentrations of TNFα compared to obese but metabolically healthy ponies (BASINSKA et 
al. 2015). 
 
2.2.2.5 Cluster of differentiation 68 
The transmembrane glycoprotein, Cluster of diferentiation (CD68), is highly expressed by 
monocytes and tissue macrophages in humans (WESTERBACKA et al. 2007). Hepatic CD68 
cells correlate with the histological severity of human NAFLD (PARK et al. 2007). A 
genetically modified mouse model further confirmed the suitability of CD68 as marker for 
Kupffer cells. The authors in that study used LIKK mice, which are known to produce elevated 
amounts of NF-κB. In comparison to wild type mice, the hepatic mRNA levels of CD68 were 
upregulated in LIKK mice. However, the authors suggested that CD68 indicates the activation 
of resident Kupffer cells rather than the recruitment of additional macrophages, as the number 
of cells did not change (CAI et al. 2005). Additionally, hepatic CD68 cells were shown to 
increase in patients with obesity compared to patients without obesity (KRISTENSEN et al. 
2017). 
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This glycoprotein has also been verified as suitable marker for macrophages in equines 
(SIEDEK et al. 2000). UNGRU et al. (2012) investigated the mRNA levels of CD68 in 
subcutaneous adipose tissue of the tail head of a population of ponies. The authors did not detect 
any differences of CD68 mRNA levels between insulin sensitive and insulin resistant obese 
ponies. After a BW reduction program for 14 weeks in the obese ponies, mRNA levels of CD68 
seemed to decrease in subcutaneous tail head adipose tissue. 
 
2.2.2.6 Chemerin 
Chemerin is a chemoattractant protein that specifically attracts macrophages and dendritic cells 
through its receptor ChemR23, thereby linking innate and adaptive immunity (WITTAMER et 
al. 2005). In addition to its role in immune function, chemerin is recognized as an adipokine 
that modulates adipogenesis and adipocyte metabolism (GORALSKI et al. 2007). Besides 
adipocytes, hepatocytes constitute a major expression site of chemerin (BUECHLER 2014). As 
reviewed by YOSHIMURA and OPPENHEIM (2008), chemerin is secreted as an inactive 
precursor protein. Chemerin is processed by various proteases into pro-inflammatory or anti-
inflammatory peptides and acts through different receptors. The multifunctional properties of 
chemerin with inhibitory and stimulatory abilities might be explained in this way. These varied 
roles of chemerin’s physiology might underlie the equivocal results of research results on 
chemerin associations with obesity, inflammation and NAFLD. 
Several studies have reported a pro-inflammatory impact of chemerin. In Mexican-American 
individuals with varying phenotypes, plasma chemerin levels correlated positively with BMI, 
fasting plasma glucose, fasting serum insulin, plasma triglycerides and total serum cholesterol 
concentrations (BOZAOGLU et al. 2009). Mice fed a high fat diet had increased hepatic mRNA 
levels of chemerin compared to animals consuming a standard diet and hepatic chemerin 
mRNA levels correlated with BW in the high fat diet group (KRAUTBAUER et al. 2013). 
Furthermore, hepatic mRNA levels of chemerin correlated positively with obesity 
measurements and severity of NAFLD in humans (DÖCKE et al. 2013). 
Other studies have substantiated the anti-inflammatory properties of chemerin. According to 
DENG et al. (2013), hepatic chemerin mRNA levels were decreased in rodents with NAFLD 
compared to control rodents without NAFLD. Furthermore, humans suffering from a 
progressive form of NAFLD displayed reduced hepatic mRNA levels of chemerin compared to 
humans suffering from steatosis alone, as initial stage of NAFLD (POHL et al. 2017). As the 
expression of cytokines in the adipose tissue is known to influence the hepatic metabolism via 
the circulatory system, some authors have investigated associations of adipokines and hepatic 
alterations. In this context, negative associations of chemerin expression in visceral adipose 
tissue with hepatic steatosis, lobular inflammation and hepatocellular ballooning have been 
reported in humans (WOLFS et al. 2015, BEKAERT et al. 2016). 
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2.2.3 Lipid metabolism 
 
2.2.3.1 Lipoprotein lipase 
One of the rate-limiting enzymes for intravascular hydrolysis of lipoprotein-rich triglyceride 
particles is LPL. It therefore helps to regulate the supply of fatty acids to various tissues. This 
enzyme is expressed at high levels in adipose tissue, heart, skeletal muscle, kidney and the 
mammary gland and at lower levels in the liver, adrenal gland and brain (KIRCHGESSNER et 
al. 1987). Insulin supports the storage of lipids by promoting the activity of LPL 
(ENGELHARDT et al. 2015). It was reported in genetically modified mice, that liver specific 
overexpression of LPL leads to hepatocellular accumulation of triglycerides and subsequently 
to hepatic insulin resistance (KIM et al. 2001). PARDINA et al. (2009) reported a significant 
increase of hepatic LPL mRNA levels in obese humans. The authors postulated that these 
changes contributed to the hepatic accumulation of triglycerides, which favors steatosis. This 
hypothesis was supported by the results of WESTERBACKA et al. (2007), who found a strong 
positive correlation between hepatic mRNA levels of LPL and hepatic lipid content in humans 
with varying amounts of histologically determined hepatic fat. 
In equine research, circulating LPL activity has been analyzed in the context of high fat feeding 
(GEELEN et al. 2000). It was shown that a ration high in fat induces plasma activity of LPL. 
This leads to decreased concentrations of circulating triglycerides and a higher availability of 
free fatty acids, which might be beneficial for the exercising horse. Concentrations of LPL in 
equine liver tissue and equine obesity have not been investigated to the author´s knowledge. 
 
2.2.3.2 Fatty acid binding protein 1 
The fatty acid binding proteins (FABP) constitute a group of proteins which are named 
according to the tissue in which they were first recognized, for example liver-type FABP 
(FABP1), intestine-type FABP (FABP2), heart-type FABP (FABP3) and adipocyte-type FABP 
(FABP4) (STORCH and CORSICO 2008). These proteins are abundant in the cellular 
cytoplasm, modulating the uptake and intracellular trafficking of long-chain fatty acids for 
oxidation and storage (WESTERBACKA et al. 2007). Of all FABP members, FABP1 is the 
most broadly distributed mammalian FABP and represents 2%–5% of the total cytosolic protein 
of the liver (ATSHAVES et al. 2010). 
In a cross-sectional study, it was shown that serum FABP1 levels were positively associated 
with obesity and insulin resistance in Chinese young adults (SHI et al. 2012). Furthermore, the 
level of hepatic FABP1 mRNA is increased in humans suffering from NAFLD, probably as a 
compensatory mechanism for increased fat influx (HIGUCHI et al. 2011). Furthermore, 
genetically modified mice lacking FABP1, were protected from high fat, high cholesterol 
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western diet-induced obesity and hepatic steatosis. The authors speculated the knockout of 
FABP1 led to subtle changes in fatty acid availability by altering food consumption, intra- and 
intercellular signaling and intestinal fatty acid uptake (NEWBERRY et al. 2006). 
In equine medicine, intestinal FABP in plasma and abdominal fluid has been investigated as a 
possible predictor of survival and need of surgical intervention in horses with colic (NIETO et 
al. 2005). However, FABP1 has neither been investigated in equines nor in the context of 
increasing equine BW. 
 
2.3 Fat-soluble vitamins in equine obesity 
Vitamins are obtained from the diet or provided by intestinal microflora and they are essential 
for diverse biological functions. Based on their relative solubility in water and fat, the 13 known 
essential vitamins are divided in two classes, fat-soluble and water soluble. The fat-soluble 
vitamins include vitamin A, D, E and K. Deficiencies of these vitamins cause commonly 
recognized clinical manifestations (vitamin A – night blindness, vitamin D – osteomalacia, 
vitamin E – increased oxidative stress and muscular disorders). But recently, deficiencies have 
been additionally associated with increased risk of cancer, type II diabetes mellitus and immune 
system disorders in humans (ALBAHRANI and GREAVES 2016). Furthermore, human 
research suggested plasma levels of fat-soluble vitamins to decrease in human obesity. Possible 
reasons were considered to be due to a lower intake of these nutrients or a higher deposition in 
adipose tissue, thus decreasing bioavailability in subjects with excess adiposity (WORTSMAN 
et al. 2000). Additionally, plasma concentrations of vitamin transport proteins are decreased by 
inflammation and therefore might diminish the bioavailability of the fat-soluble vitamins in 
chronic inflammation accompanying obesity (ROSALES and ROSS 1998). 
 
2.3.1 Vitamin E 
Vitamin E includes eight lipophilic variants, namely α-, β-, γ-, and δ-tocopherol and α-, β-, γ-, 
and δ-tocotrienol of which α-tocopherol is the predominant form in whole body tissues in 
humans (JIANG 2014). Vitamin E has several functions, which include modulation of gene 
expression (e. g. scavenger receptors, α-tropomyosin, matrix metalloproteinase-19 and 
collagenase), inhibition of cell proliferation, platelet aggregation, monocyte adhesion (ZINGG 
and AZZI 2004), and regulation of bone mass (FUJITA et al. 2012). Moreover, α -tocopherol 
is one of the main fat-soluble antioxidants (BURTON and TRABER 1990). As major fat-
soluble antioxidant, α-tocopherol combats lipid peroxidation of cell membranes and interrupts 
the radical chain by forming derivative that has low reactivity and is unable to attack lipid 
substrates (DESCAMPS-LATSCHA et al. 2001). In humans, α-tocopherol is in the group of 
exogenous antioxidants, such as β-carotenes, ascorbic acid and others which complement the 
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actions of endogenous antioxidants such as uric acid, superoxide dismutase and melatonin 
(PISOSCHI and POP 2015). Antioxidant defenses are necessary to fight reactive oxygen 
species. Reactive oxygen species are produced by aerobic processes such as cellular respiration, 
microbial infection and intensive physical exercise (POLJSAK et al. 2013). Imbalances 
between antioxidant defenses and reactive oxygen species production result in oxidative stress. 
Oxidative stress leads to structure modifications and function modulation in nucleic acids, lipids 
and proteins. Several markers of oxidative damage are known to be specific to the disturbed 
tissue type. Imbalances between the reactive oxygen species and the antioxidant system are 
involved in many diseases and can ultimately lead to cancer, neurodegeneration, cardiovascular 
disease, diabetes and kidney dysfunction (PISOSCHI and POP 2015). Additionally, oxidative 
stress has been reported to be associated with obesity in humans and is suspected to be partly 
responsible for comorbidities of human obesity such as atherosclerosis (D'ARCHIVIO et al. 
2012, TIBAUT and PETROVIČ 2016). 
As consequence of these findings, the interrelations of serum α-tocopherol concentrations and 
human obesity have been studied intensively. Most human studies detected negative 
associations between serum α-tocopherol and obesity and suggested a depletion of circulating 
α-tocopherol due to elevated oxidative stress, reduced dietary antioxidant intake or entrapment 
of vitamin E in the expanding adipose tissue as causative factors (DECSI et al. 1997, 
BOTELLA-CARRETERO et al. 2010, GUNANTI et al. 2014). Some opposing studies reported 
positive correlations of serum α-tocopherol concentrations and obesity in humans 
(WALLSTRÖM et al. 2001, WANIEK et al. 2017). However, most investigations of serum α-
tocopherol in obese humans have been limited by the lack of the ability to standardize intake of 
vitamin E in the study populations. 
The recommended daily dietary intake of vitamin E in adult horses is 5 IU/kg BW0.75 per day 
according to the guidelines of the Society of Nutrition Physiology (GfE 2014) 
(FLACHOWSKY et al. 2014). Sufficient supply of vitamin E in horses is important to prevent 
equine degenerative myeloencephalopathy (FINNO et al. 2011), equine motor neuron disease 
(DIVERS et al. 2006) and nutritional myodegeneration (along with sufficient selenium supply) 
(LÖFSTEDT 1997). Vitamin E in equine research was frequently evaluated in the context of 
performance parameters during exercise which induces oxidative stress (MCBRIDE and 
KRAEMER 1999), although proof of beneficial effects of vitamin E supplementation in 
exercising horses is lacking (SICILIANO et al. 1997, WILLIAMS et al. 2005). In the context 
of obesity, contradictory results regarding vitamin E have been reported in horses. Markers of 
oxidative stress and antioxidant function were not altered in obese horses or prelaminitic ponies 
when compared to healthy controls (TREIBER et al. 2009, HOLBROOK et al. 2012). On the 
other hand, other equine studies detected reduced antioxidative capacities in obese horses 
(PLEASANT et al. 2013) and in horses suffering from EMS (MARYCZ et al. 2018). 
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2.3.2 Vitamin A 
Vitamin A (retinol) is the parent compound of all bioactive retinoids and retinoic acid 
constitutes the active metabolite of vitamin A. Approximately 80-90% of all retinoids are stored 
as retinyl esters in the liver. In general, serum retinol concentrations are maintained within a 
narrow range in individuals with adequate liver retinol stores independent of the diet (MODY 
2017). The biological effects of retinoids are mediated by two types of nuclear receptors, the 
retinoic acid receptor and retinoid X receptor, both mediating transcriptional activity 
(VILLARROYA et al. 2004). In addition to the essential function of vitamin A for vision 
(HYATT and DOWLING 1997), the influence of vitamin A on inflammation (e.g. in infections 
like measles or malaria, gastrointestinal tract and respiratory tract inflammation) has been 
reviewed several times in the human literature (SEMBA 1999, STEPHENSEN 2001, REIFEN 
2002). Beneficial effects of a vitamin A supplementation, such as enhancement of phagocytic 
activity of neutrophils and macrophages have been reported as vitamin A is often decreased in 
inflammation in humans (SEMBA 1999, STEPHENSEN 2001, REIFEN 2002). Furthermore, 
ROSALES et al. (1996) reported that an injection of lipopolysaccharides, which induce 
systemic inflammation, decreased the serum retinol concentrations in rats. More recent studies 
have linked vitamin A to the regulation of adipogenesis, insulin sensitivity, and glucose 
homeostasis in humans, rats and mice. For example, the administration of retinoic acid 
prevented BW gain and improved insulin sensitivity in genetically obese mice (MANOLESCU 
et al. 2010). In a study population of morbidly obese human subjects, inadequate serum vitamin 
A levels were correlated with the presence of insulin resistance (VILLAÇA CHAVES et al. 
2008). These authors concluded that it is important to maintain a sufficient supply of vitamin 
A to prevent a complete conversion of dietary β-carotene, an important exogenous antioxidant, 
into retinol since β-carotene is the precursor for hepatic synthesis of retinol. Therefore, β-
carotene can fulfill its antioxidative functions instead of only converting into retinol (VILLAÇA 
CHAVES et al. 2008). 
Several field studies reported conflicting data about the relationship between human obesity 
and serum retinol concentrations. However, most authors found decreased serum retinol levels 
in obese adults (AASHEIM et al. 2008, BOTELLA-CARRETERO et al. 2010, PEREIRA et al. 
2012) and proposed several mechanisms as possible causative factors: imbalanced nutrition in 
obese subjects, entrapment of fat-soluble vitamins in enlarged adipose tissue depots and 
inflammation accompanying obesity. On the contrary, increasing amounts of serum retinol with 
increasing body condition were reported in children under 15 years (AEBERLI et al. 2007, 
GUNANTI et al. 2014). The differences in age of the study populations may have caused these 
discrepancies which did not take into account the impacts of growth or puberty in young 
humans. Of further note, the main limitation of human studies investigating circulating retinol 
levels is the lack of the ability to standardize vitamin A intake in the study populations. 
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Similar to humans, deficiencies of vitamin A in equines were described to cause loss of vision, 
defects in bone growth, defects in reproduction, defects in growth and differentiation of 
epithelial tissues, and lowered resistance to disease and infection (CRANDELL 1998). 
According to the GfE 2014 the recommended daily dietary intake of vitamin A in adult horses 
is 150 IU/kg BW0.75 per day (FLACHOWSKY et al. 2014). However, detailed research of 
retinol interactions in equines are limited and have been mainly focused on performance and 
parturition effects on circulating vitamin A concentrations (ABRAMS 1979, BUTLER and 
BLACKMORE 1982, SCHWEIGERT and GOTTWALD 1999). 
 
2.3.3 Retinol-binding protein 4 
Retinol is transported in the blood by retinol-binding protein 4 (RBP4) which is primarily 
synthesized in the liver. Alterations of vitamin A intake also affect hepatic release of RBP4 in 
humans (BLANER 1989). In addition to hepatic secretion, RBP4 also is released from adipose 
tissue as an adipokine (TAMORI et al. 2006). 
RBP4 has been suggested to play an important role in the pathogenesis of metS (KLOTING et 
al. 2007). This assumption was supported by YANG et al. (2005), who showed that the injection 
of purified RBP4 into mice or transgenic overexpression of RBP4 in mice causes insulin 
resistance. Adipocytes had decreased GLUT4 expression in insulin resistant humans and 
rodents (SHEPHERD and KAHN 1999). The study by YANG et al. (2005) suggested that 
adipocytes respond to decreased GLUT4 expression by secreting RBP4. Subsequently, RBP4 
inhibits insulin signaling in muscles and increases circulating blood glucose by inducing hepatic 
gluconeogenesis, factors which promote systemic insulin resistance. However, these findings 
about RBP4 have been controversial. Opposing studies suggest that the observed association 
between plasma RBP4 concentrations and insulin resistance is less important in humans than 
in mice and rats (RIBEL-MADSEN et al. 2009). In addition, the metabolic syndrome is related 
to kidney dysfunction which results in elevated serum RBP4 concentrations. Therefore, the 
observed elevated serum RBP4 in patients suffering from type 2 diabetes mellitus may result 
from moderate renal insufficiency rather than obesity associated alterations. (HENZE et al. 
2008). 
Furthermore, data resulting from human clinical studies are conflicting. In several studies, 
serum RBP4 levels were reported to be associated with insulin resistance, obesity 
measurements and oxidative stress in humans (YANG et al. 2005, GRAHAM et al. 2006, 
AEBERLI et al. 2007, LIU et al. 2014b). However, other studies did not detect correlations 
between serum RBP4 levels and BMI or insulin resistance (JANKE et al. 2006, LEWIS et al. 
2007, SHEA et al. 2007, YAO-BORENGASSER et al. 2007). Technical problems such as 
sample collection method, e.g. type of collection tubes or the antibody design for the 
immunoassay, may have led to inaccurate measurements of circulating RBP4 concentrations. 
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Additionally, the genetic background of the investigated study populations, age, sex, kidney 
function, retinol status and iron status are confounding factors affecting the results of the 
aforementioned studies and therefore perhaps contributing to the different outcomes (KOTNIK 
et al. 2011). 
It has been recommended to include measurement of serum retinol concentrations in the studies 
of serum RBP4 concentrations by calculating the retinol/RBP4 ratio (MILLS et al. 2008, 
ERIKSTRUP et al. 2009) as circulating RPB4 concentrations are mainly influenced by retinol 
status (BLANER 1989). In the study population of MILLS et al. (2008), differences between 
obese and non-obese humans became highly significant by calculating the retinol/RBP4 ratio. 
The same population showed moderate differences by only comparing serum RBP4 levels. The 
retinol/RBP4 ratio has been reported to decrease with increasing human obesity (AEBERLI et 
al. 2007, MILLS et al. 2008) 
Similar to human research, equine studies of RBP4 have revealed equivocal results. Horses 
with EMS had increased RBP4 mRNA levels in adipose tissue and liver in comparison to 
healthy control horses (MARYCZ et al. 2018). Similarly, UNGRU et al. (2012) reported serum 
RBP4 concentrations to decrease in obese ponies undergoing a BW reduction program. On the 
contrary, SELIM et al. (2015) detected a negative correlation between tailhead subcutaneous 
adipose tissue RBP4 expression and BW in grazing mares. 
Publications 
 
18 
 
3 Publications 
3.1 Impact of body weight gain on hepatic metabolism and hepatic 
inflammatory cytokines in comparison of Shetland pony geldings 
and Warmblood horse geldings 
C. Schedlbauer, D. Blaue, M. Gericke, M. Blüher, J. Starzonek, C. Gittel, W. Brehm and I. 
Vervuert 
PeerJ 2019, DOI 10.7717/peerj.7069 
 
Contributions 
I. Vervuert created the study design. S. Klemann, J. Starzonek, D. Blaue and I fed the equines 
and took care for them. BW, BCS and CNS were assessed weekly by D. Blaue and me. Blood 
samples for assessment of liver enzyme activities and BA were collected by J. Starzonek, D. 
Blaue and me. Dr. W. Brehm conducted the liver tissue sampling in general anesthesia with 
assistance of D. Blaue, J. Starzonek and me. Organization and care for the animals before and 
after surgery was provided by D. Blaue and me under supervision of C. Gittel. The laboratory 
of the Large Animal Clinic of the Faculty of Veterinary Medicine in Leipzig analyzed liver 
enzyme activities and BA in provided blood samples. Preparation of histological slides of liver 
samples was done by D. Blaue and me. M. Gericke staged the histological liver samples 
according to their lipid content. The RT-qPCR of liver samples for analysis of markers for 
inflammation and lipid metabolism was done by me. Statistical analysis of the results was 
conducted by me. I wrote the first draft of all parts of the manuscript and revisions were done 
by D. Blaue, J. Starzonek and I. Vervuert. All coauthors revised the final manuscript and 
approved it for publication. 
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Supplemental material 
Table 1: Descriptive data of the ponies and horses at the beginning of the study 
 Shetland ponies Warmblood horses 
Sex 10 geldings 9 geldings 
Age, years 6 ± 3 10 ± 3 
Body weight, kg 118 ± 29 589 ± 58 
Body condition score (BCS), 
0-5 (CARROLL and HUNTINGTON 
1988) 
2.3 (1.2/3.4) 2.7 (2.1/3.2) 
Cresty neck score (CNS), 
0-5 (CARTER et al. 2009a) 
2.5 (0.8/3) 2 (1.8/2.3) 
Plasma adrenocorticotropic hormone 
(ACTH), pg/mL 
Threshold: 50 pg/mL 
15.9
 
(12.8/17.1) 16.4 (15.1/19.6) 
Leukocytes (G/L) 
t0 
t2 
t5 
7.87 ± 1.26 
6.18 ± 2.23 
6.93 ± 2.09 
5.14 ± 0.72 
5.58 ± 1.6 
5.88 ± 1.12 
Erythrocytes 
(T/L) 
t0 
t2 
t5 
6.15 ± 0.6 
6.53 ± 0.59 
6.87 ± 0.96 
6.52 ± 0.43 
7.39 ± 0.8 
7.92 ± 0.98 
Hemoglobin 
(mmol/L) 
t0 
t2 
t5 
6.17 ± 0.67 
6.58 ± 0.61 
6.93 ± 0.77 
6.93 ± 0.43 
7.71 ± 0.72 
8.13 ± 0.69 
 1Mean of two independent evaluators. Age, BW, leukocytes, erythrocytes and hemoglobin 
are presented as mean (± SD); BCS, CNS and ACTH are presented as median (25th/75th 
percentiles) 
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Table 2: Plasma glucose concentrations (mmol/L) and serum insulin concentrations (µU/mL) 
for two sampling points (0 and 45 minutes after insulin bolus) during combined glucose insulin 
test (CGIT) at basal measurements (t0), after one year (t2) and after two years (t5) of excess 
energy intake 
Variable 
Sampling 
point 
Breed t0 t2 t5 
Glucose 
(mmol/L) 
0 
Ponies 3.53  ± 0.63 3.93  ± 0.38 4.34  ± 0.86 
Horses 4.08  ± 0.20 4.52  ± 0.22 4.41  ± 0.47 
45 
Ponies 3.79  ± 1.24 2.4  ± 1.08 3.25  ± 1.59 
Horses 3.72  ± 1.34 3.18  ± 0.98 3.89  ± 1.94 
Insulin 
(µU/mL) 
0 
Ponies 4.26  ± 1.36 7.93 ± 5.75 13.9 ± 14.9 
Horses 6.32 ± 2.35 9.3 ± 3.18 15.1 ± 10.3 
45 
Ponies 26.1  ± 13.1 37.6 ± 11. 1 62.2 ± 38.4 
Horses 37.5  ± 14.1 51 ± 16.2 85.6 ± 54.4 
Data are expressed as mean ± SD 
 
 
Table 3: Serum amyloid A (SAA) concentrations (µg/mL) at basal measurements (t0), after 
one year (t2) and after two years (t5) of excess energy intake in ponies and horses 
Variable Breed t0 t2 t5 
SAA  
(µg/mL) 
Ponies 0.35 ± 0.5 0.24 ± 0.22 0.1 ± 0 
Horses 0.1 ± 0 0.1 ± 0 0.1 ± 0 
Data are expressed as mean ± SD 
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Table 4: Hepatic mRNA levels of TNFα, IL-6, FABP1 and CD68 (x-fold) at basal 
measurements (t0), after one year (t2) and after two years (t5) of excess energy intake in ponies 
and horses 
Variable Breed t0 t2 t5 
TNFα 
(x-fold) 
Ponies 
0.62 
(0.46/0.81) 
0.69 
(0.45/0.79) 
0.73 
(0.67/1.18) 
Horses 
0.45 
(0.37/0.51) 
0.52 
(0.33/0.71) 
0.64 
(0.49/0.77) 
IL-6 
(x-fold) 
Ponies 
0.29   
(0.25/0.8) 
0.27 
(0.24/0.34) 
0.62   
(0.4/0.79) 
Horses 
0.29 
(0.25/0.33) 
0.27 
(0.17/0.38) 
0.44 
(0.26/0.53) 
FABP1 
(x-fold) 
Ponies 
0.71 
(0.55/0.73) 
0.4     
(0.36/0.6) 
0.68 
(0.42/0.77) 
Horses 
0.71 
(0.42/0.81) 
0.52 
(0.49/0.64) 
0.71   
(0.5/0.94) 
CD68 
(x-fold) 
Ponies 
0.72 
(0.65/0.83) 
0.77 
(0.48/1.15) 
0.65 
(0.52/0.76) 
Horses 
0.53 
(0.43/0.64) 
0.53 
(0.47/0.55) 
0.49   
(0.4/0.52) 
Data are presented as medians and 25th/75th percentiles 
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3.2 Alterations of serum vitamin E and vitamin A concentrations of 
ponies and horses during experimentally induced obesity 
C. Schedlbauer, D. Blaue, J. Raila and I. Vervuert 
J Anim Physiol Anim Nutr. 2020;00:1–8. (https://doi.org/10.1111/jpn.13385) 
Contributions 
The study design was created by I. Vervuert. The ponies and horses were fed and groomed by 
S. Klemann, J. Starzonek, D. Blaue and me. Together with D. Blaue I determined the BW, BCS 
and CNS of all equines every week. Blood sampling for assessment of serum vitamin A, vitamin 
E and RBP4 concentrations was conducted by me, D. Blaue and J. Starzonek. Analysis of blood 
parameters was done by J. Raila and his laboratory assistance. Interpretation and statistical 
analysis of results was done by me. I wrote the first draft of all parts of the manuscript and it 
was revised by D. Blaue, J. Starzonek and I. Vervuert. All coauthors revised the final 
manuscript and approved it for publication. 
 
  
Publications 
 
43 
 
 
 
 
 
 
Publications 
 
44 
 
 
 
 
 
Publications 
 
45 
 
 
 
 
 
Publications 
 
46 
 
 
 
 
 
Publications 
 
47 
 
 
 
 
 
Publications 
 
48 
 
 
 
 
 
Publications 
 
49 
 
 
 
 
 
Publications 
 
50 
 
  
Discussion 
 
51 
 
4 Discussion 
As expected, the experimental design of the present study induced a significant increase in BW, 
BCS and CNS in ponies and horses. Notably, the achieved BW gain of our equines was less 
than in previous studies (CARTER et al. 2009b, SIEGERS et al. 2018). CARTER et al. (2009) 
and SIEGERS et al. (2018) fed a ration in which energy intake was provided by approximately 
60% concentrate and 40% roughage. In contrast, the energy intake in the present study was 
provided by 40% concentrate and 60% roughage. Furthermore, equines of our study were 
supplied with less starch and more fibre than the equines of the aforementioned studies. These 
differences in ration composition probably caused the lower BW gain in the present study. 
However, the ration was chosen out of equine welfare concerns during a long-term observation 
period and its closer relation to practical feeding regimens in horses. High grain rations have 
been associated for example with colic and laminitis (ROWE et al. 1994, LOPES et al. 2004). 
4.1 Impact of body weight gain on hepatic lipid metabolism 
The majority of our equines did not develop steatosis after two years of BW gain according to 
histological evaluation of the liver biopsies. This contrasts with a study of KECHAGIAS et al. 
(2008), who demonstrated a 2.5-fold increase of liver fat in lean and healthy humans following 
a BW gain of 5-15% within four weeks. It has to be noted that dietary fat content itself, 
independent from caloric intake, promotes the development of steatosis in mice (MEIJER et al. 
2010). This might explain the discrepancy to the study of KECHAGIAS et al. (2008), as the 
humans consumed 3.5-fold the amount of fat as percent of total intake daily compared to our 
equines. It was further shown that the hepatic lipid metabolism of our equines was not 
profoundly affected by BW gain, as hepatic mRNA levels of LPL and FABP1 were unaltered. 
Hepatic mRNA levels of LPL were reported to increase in human obesity and thereby to 
promote steatosis (PARDINA et al. 2009). Increased hepatic mRNA levels of FABP1 in 
humans with steatosis were suggested to compensate for the increased fat influx (HIGUCHI et 
al. 2011). In the current study, the degree of obesity might have been too low to alter hepatic 
lipid accumulation and lipid metabolism. SIEGERS et al. (2018) reported a limited 
expandability of subcutaneous adipose tissue in Shetland ponies with excess fat storage 
occurring in retroperitoneal tissue instead. Therefore, BW gain of our equines might not have 
been sufficient to exceed the expandability of subcutaneous adipose tissue and subsequently, 
fat did not accumulate in other sites like abdominal adipose tissue or liver. 
Despite finding no profound changes of hepatic lipid metabolism induced by increasing BW in 
our equines, we did detect moderate differences between ponies and horses. Ponies showed 2.4-
fold higher hepatic mRNA levels of LPL compared to horses at the end of the study. According 
to PARDINA et al. (2009), this finding may increase the risk of the ponies to develop steatosis 
as consequence of enhanced hepatic uptake of circulating triglycerides. Histological evaluation 
of hepatic lipid content sustains this assumption. While the percentage of horses with hepatic 
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lipid content of more than 5% decreased marginally from the start of the study (33%) to the end 
of the study (11%), the percentage of ponies exhibiting a hepatic lipid content of more than 5% 
increased from 20% at the beginning of the study to 40% at the end of the study. The ponies 
therefore seemed to be more susceptible to hepatic lipid accumulation in early stages of obesity 
than were the horses. 
4.2 Impact of body weight gain on serum liver enzyme activities and bile 
acids 
Serum liver enzyme activities and serum BA concentrations represent useful markers for 
evaluation of liver metabolism. In the present study, serum AST, ALP and GGT activities were 
not altered by BW gain over two years in ponies and horses. However, ponies had higher serum 
AST activities over the course of the study compared to horses, but the serum AST activities of 
ponies were still within the reference range. Serum GLDH activities and serum BA increased 
in ponies during BW gain, but not in horses. Both parameters are specific for hepatic alterations. 
Bile acids are not only mediators for nutrient absorption, but also signaling molecules for lipid 
and glucose metabolism (MA and PATTI 2014). Plasma BA concentrations correlated 
positively with insulin resistance (HAEUSLER et al. 2013) and disease severity of NAFLD in 
humans (BECHMANN et al. 2013). We speculate that the livers of ponies were more affected 
by the development of obesity than the livers of horses, as BW gain did not alter any liver 
associated serum parameter in horses. 
4.3 Impact of body weight gain on hepatic mRNA levels 
Several human studies reported a link between pro-inflammatory cytokines and obesity 
associated NAFLD (HAUKELAND et al. 2006, MANCO et al. 2007, KAMARI et al. 2011) 
but this implication had not previously been investigated in equines. In the present study, 
hepatic mRNA levels of well-established pro-inflammatory cytokines (TNFα, IL-6, IL-1β) and 
macrophage marker CD68 were not affected by BW gain, either in ponies, or horses. Moreover, 
hepatic mRNA levels of NF-κB, decreased in horses at the end of the study. NF-κB is a 
transcription activator of pro-inflammatory cytokines, chemokines, inflammatory enzymes and 
adhesion molecules (BARNES 1997). In mice, hepatocellular inflammation with subsequent 
production of pro-inflammatory cytokines was induced by steatosis (CAI et al. 2005). 
Therefore, our findings of unaltered hepatic pro-inflammatory cytokines are in agreement with 
unaltered hepatic lipid content in most equines in this study. We speculate that the duration of 
obesity might have been too short or that the degree of obesity might have been insufficient to 
have detrimental effects on hepatic inflammatory pathways. 
We also investigated chemerin which was described as adipokine with regulatory roles in 
adipogenesis and adipocyte metabolism (GORALSKI et al. 2007). The exact functions of 
chemerin are recently under discussion as some studies provided evidence for a pro-
inflammatory role of chemerin (WEIGERT et al. 2010, CHAKAROUN et al. 2012), while 
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opposing studies proposed chemerin to exert anti-inflammatory properties (CASH et al. 2008, 
LUANGSAY et al. 2009). These discrepancies might be explained by the various pathways 
following the secretion of chemerin. Different proteases convert pro-chemerin into pro-
inflammatory or anti-inflammatory peptides which are able to act through 3 different receptors 
with different functions (YOSHIMURA and OPPENHEIM 2008). According to opposing data 
of fundamental functions of chemerin, investigations on the associations of chemerin and 
NAFLD have provided equivocal results. For example, DÖCKE et al. (2013) reported a positive 
correlation of hepatic mRNA chemerin levels with obesity measurements, such as BMI and 
NAFLD severity in humans. Similarly, BW gain caused a significant increase of hepatic 
chemerin mRNA levels in ponies and horses in the present study. However, rodents with 
NAFLD had decreased hepatic chemerin mRNA levels compared to control rodents without 
NAFLD (DENG et al. 2013). Interestingly, horses but not ponies showed a negative correlation 
between hepatic mRNA levels of chemerin and NF-κB. This result implies a possible anti-
inflammatory role for chemerin in conditions of increasing BW in horses. Since hepatic 
chemerin mRNA levels distinctly responded to BW gain in contrast to classical pro-
inflammatory cytokines, chemerin may represent an interesting marker for future equine 
obesity research. 
4.4 Impact of body weight gain on serum vitamin E (α-tocopherol) levels 
The majority of previous studies in humans revealed negative associations between serum α-
tocopherol levels and obesity (BOTELLA-CARRETERO et al. 2010). Authors suggested 
increased oxidative stress secondary to obesity as causative factor for the decrease of serum α-
tocopherol. However, some contradictory studies reported positive correlations of serum α-
tocopherol and obesity in humans (WALLSTRÖM et al. 2001). In our study, serum α-
tocopherol concentrations had a robust positive association with α-tocopherol intake in both 
ponies and horses. This suggests a dietary cause for increasing serum α-tocopherol 
concentrations in the course of our study, rather than a BW gain impact. This statement is 
further strengthened as vitamin E intake of the ponies and horses was 2.5-3-fold above the 
maintenance requirements (FLACHOWSKY et al. 2014). The assumption of a dose-response 
relationship of vitamin E supplementation is supported by former studies. An almost linear 
dose-response relationship between vitamin E intake and blood concentrations was reported by 
RONÉUS et al. (1986), who supplemented different dosages of synthetic α-tocopherol over 112 
days to clinically healthy Standardbreds. In another study high vitamin E supplementation 
resulted in higher serum α-tocopherol concentrations compared to a moderate vitamin E intake 
in adult equines (KIENZLE et al. 2003). 
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4.5 Impact of body weight gain on serum vitamin A (retinol) and RBP4 
levels 
Retinol, an intensively investigated parameter in human obesity research, is described as anti-
inflammatory factor (REIFEN 2002) that also improves insulin sensitivity (MANOLESCU et 
al. 2010). Equivocal results have been found regarding the association of human obesity with 
serum retinol concentrations. Some studies reported decreased serum retinol concentrations in 
obese Caucasian individuals (BOTELLA-CARRETERO et al. 2010), whereas others described 
increasing levels of serum retinol with increasing body condition in Mexican-American 
children (GUNANTI et al. 2014). Other authors detected no differences in serum retinol 
concentrations between different BMI groups (MILLS et al. 2008). However, human studies 
are mainly limited by the lack of standardization of vitamin A intake. It has to be noted that 
serum retinol concentrations are maintained within a narrow range independent of the diet in 
individuals with adequate liver retinol stores. (MODY 2017). Serum retinol concentrations 
showed some minor fluctuations over the BW gaining period in ponies and horses, but changes 
were probably of little biological significance. Furthermore, the dietary intake of vitamin A and 
serum retinol concentrations were not correlated. It is likely that liver retinol stores were 
adequate in our ponies and horses, as supply of retinol was 1.7-2.4-fold above maintenance 
requirements. 
Retinol is transported in the blood by RBP4, and alterations of vitamin A intake affect hepatic 
release of RBP4 in humans (BLANER 1989). RBP4, besides being a transport protein, has been 
identified as an adipokine in humans and horses (TAMORI et al. 2006, UNGRU et al. 2012). 
Human and equine studies provided equivocal results about the metabolic impacts of RBP4. 
On the one hand, a positive correlation of serum RBP4 concentrations and insulin resistance, 
obesity measurements, oxidative stress and the risk of developing metS has been reported in 
humans (LIU et al. 2014b). In agreement, a BW reduction program in obese ponies led to a 
decrease in serum RBP4 levels (UNGRU et al. 2012). On the other hand, human subjects with 
different BMI showed no differences in serum RBP4 (LEWIS et al. 2007). Furthermore, tail 
head RBP4 gene expression and BW were negatively associated in grazing mares (SELIM et 
al. 2015). In agreement with SELIM et al. (2015) we found an inverse relation between serum 
RBP4 and obesity in ponies and horses. Additionally, we detected a negative correlation 
between serum insulin and serum RBP4 in ponies. That finding is in contrast to the study of 
YANG et al. (2005), who stated that RBP4 favors insulin resistance in mice. 
It has been recommended to include serum retinol concentrations, the most important 
determinant of RBP4, in the evaluation of RBP4 by calculating the serum retinol/RBP4 ratio 
(MILLS et al. 2008). Serum RBP4 concentrations were moderately different between obese and 
non-obese humans, while the differences between the groups became highly significant when 
using the retinol/RBP4 ratio. The retinol/RBP4 ratio decreased with increasing obesity (MILLS 
et al. 2008). In contrast to these previous results in humans, BW gain in the present study 
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induced an increase of the retinol/RBP4 ratio in equines. Furthermore, we did not detect a 
positive association between serum retinol and RBP4 concentrations. These findings indicate 
that the knowledge gained from human studies cannot be transferred to the equine. Further 
research is necessary to elucidate the interactions and physiological mechanisms of retinol and 
RBP4 in equines. 
4.6 Laminitic equines 
One pony and one horse developed laminitis at the end of the study. These two equines 
exhibited some differences compared to their respective cohorts. CARTER et al. (2009b) 
characterized specific cut-off values for insulin (>32 µU/mL), leptin (>7.3 ng/mL), BCS (≥7/9), 
CNS (≥4/5) for reproducible diagnostic accuracy for the prediction of pasture-associated 
laminitis. Supporting the importance of CNS, the CNS of the laminitic pony was 4.5 at the end 
of the study. However, the laminitic horse had a CNS of 3, which is below the cut-off value of 
CARTER et al. (2009b). In 64.3% of obese horses with a history of laminitis CHAMEROY et 
al. (2011) reported elevated serum GGT activities and speculated hepatic lipidosis as possible 
causative factor. In agreement with those results, serum GGT activities of the laminitic pony 
exceeded the reference range and furthermore, the liver biopsy showed steatosis stage 1 at the 
end of the study. On the other hand, liver enzyme activities and liver steatosis stage were within 
physiological ranges in the laminitic horse. As hepatic mRNA levels of pro-inflammatory 
cytokines in laminitic equines were not different in comparison to respective cohorts, it seems 
unlikely that hepatic inflammatory processes contributed to the development of laminitis. 
Interestingly, we found 1.8 times lower- and 3.2-times lower serum α-tocopherol concentrations 
in the laminitic pony and the laminitic horse, respectively, compared to the mean of their 
respective cohorts. The equine digital laminae are highly susceptible to oxidative damage as 
they are lacking superoxide dismutase, an important antioxidant enzyme (LOFTUS et al. 2007). 
Therefore, systemic antioxidant capacity might be extraordinarily important for integrity of 
digital laminae. We speculated that decreased serum α-tocopherol concentrations in the affected 
pony and horse were induced by higher demands of antioxidants in the laminar tissue due to 
laminitis. This speculation agrees with the study of YIN et al. (2009), who stated that oxidative 
stress may play an important role in the laminar failure in laminitis. Consequently, laminitic 
equines might benefit from vitamin E supplementation dosages exceeding the 3-fold 
maintenance requirements. However, this speculation needs to be verified in further studies 
with more laminitic equines and a more detailed assessment of the very complex 
oxidant/antioxidant equilibrium. 
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4.7 Conclusion 
In contrast to our original hypotheses, liver steatosis seemed not to be an integral part of early 
stages of equine obesity. However, ponies and horses exhibited breed-related differences in 
parameters such as steatosis stage, serum GLDH activities, serum BA concentrations and 
hepatic mRNA levels of LPL. In agreement with our original hypotheses, these differences 
might suggest that livers of ponies are more affected by early stages of obesity than in horses. 
These breed-related differences might be involved with the reported higher predisposition of 
pony breeds for metabolic disturbances. In contrast to our hypotheses, BW gain did not increase 
liver mRNA levels of pro-inflammatory cytokines such as TNFα or IL-6. However, chemerin 
significantly increased during BW gain in ponies and horses. Chemerin was therefore identified 
as a potentially interesting hepatic marker for equine obesity research, although it remains 
unknown whether chemerin may have anti- or pro-inflammatory properties. Serum α-
tocopherol concentrations were less affected by BW gain but showed a strong dose-response 
relationship by the supplementation of synthetic α-tocopherol. Although the number of affected 
animals was limited, the decrease in serum α-tocopherol concentrations related to an episode 
of laminitis may reflect the higher demand of antioxidants in laminar tissue. This important 
finding needs further elucidation to specify the recommendation for vitamin E intake of 
laminitis prone equines. 
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Introduction 
Obesity is an increasing health problem in humans and domestic animals such as horses. Some 
equine breeds, such as pony breeds are predisposed to obesity and its consequences. The 
underlying reasons are not fully elucidated. It is known that human obesity goes along with 
fatty alterations of the liver, termed non-alcoholic fatty liver disease, which lead to 
hepatocellular inflammation. It is not known, however, whether equine obesity induces 
alterations of liver metabolism as well. In addition to hepatocellular inflammation, human 
obesity is accompanied by systemic inflammation and increased oxidative stress. Therefore, 
anti-inflammatory/antioxidant substances such as vitamin A (retinol) and vitamin E (α-
tocopherol) have been intensively investigated in human research. Both vitamins were often 
described to decrease in obese conditions. 
Aim of the study 
The current investigation aimed to assess the impact of body weight (BW) gain in ponies and 
horses on several parameters: (1) serum liver enzyme activities and bile acids (BA), (2) hepatic 
lipid content, (3) hepatic messenger ribonucleic acid (mRNA) levels of markers of 
inflammation and lipid metabolism and (4) serum levels of retinol and α-tocopherol. 
Furthermore, we aimed to compare ponies and horses to identify possible reasons for the higher 
susceptibility of ponies for obesity related metabolic disturbances. 
Materials and Methods 
Ten Shetland ponies and 9 Warmblood horses, all non-obese, were fed 200% of their 
maintenance requirements for metabolizable energy over two years. Body weight, body 
condition score (BCS) and cresty neck score (CNS) were assessed weekly. Blood sampling was 
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conducted 6 times for analysis of serum liver enzyme activities (alkaline phosphatase (ALP), 
aspartate aminotransferase (AST), glutamate dehydrogenase (GLDH), gamma-glutamyl 
transferase (GGT)) and BA and 7 times for analysis of serum retinol and α-tocopherol during 
the experimental period. Three times during the study, liver tissue was sampled under general 
anesthesia via laparotomy. Liver biopsies were analyzed for lipid content by histological 
evaluation and for pro-inflammatory markers (nuclear factor-κB (NF-κB), interleukin-1β (IL-
1β), IL-6, tumor necrosis factor α (TNFα), cluster of differentiation 68 (CD68), chemerin) and 
markers of lipid metabolism (lipoprotein lipase (LPL), fatty acid binding protein 1 (FABP1)) 
by real-time quantitative polymerase chain reaction (RT-qPCR). The data were analyzed using 
a statistical software program (STATISTICA, version 12, StatSoft GmbH, Hamburg, 
Germany). After analyzing normal distributions, the appropriate tests were applied with 
statistical significance at P < 0.05. The Ethics Committee for Animal Rights Protection of the 
Leipzig District Government (No. TVV 32/15) approved the project in accordance with German 
legislation for animal rights and welfare. 
Results 
Ponies and horses showed a significant increase in BW (mean ± SD; ponies: 29.9 ± 19.4%; 
horses: 17 ± 6.74%), BCS (median (25th/75th percentiles); ponies: 157% (115/349); horses: 
142% (128/192)) and CNS (median (25th/75th percentiles); ponies: 165% (123/500); horses: 
200% (160/225)) due to the hypercaloric feeding over the course of the two years. Body weight 
gain did not induce steatosis in the majority of equines. Liver mRNA levels of IL-6, TNFα, 
CD68 and IL-1β did not change during BW gain. Body weight gain induced a significant 
increase of liver mRNA chemerin levels in ponies (x-fold increase: 1.89) and horses (x-fold 
increase: 2.04). Significant differences in serum GLDH activities, serum BA concentrations 
and hepatic mRNA levels of LPL were observed between ponies and horses at the end of the 
study. Serum α-tocopherol concentrations increased significantly in ponies and horses during 
BW gain and circulating α-tocopherol levels correlated positively with α-tocopherol intake. 
Serum retinol concentrations showed fluctuations during the feeding period without correlating 
with the intake of vitamin A. 
Conclusions 
Early equine obesity does not necessarily lead to steatosis and subsequent hepatocellular 
inflammation. Nonetheless, hepatic metabolism exhibits differences between obese ponies and 
horses. That might explain in part the greater susceptibility of ponies to obesity-associated 
metabolic disturbances. Additionally, chemerin was identified as an interesting marker for 
future equine obesity research. Body weight gain in equines does not seem to affect serum 
concentrations of retinol and α-tocopherol in equines fed above recommended intakes of these 
antioxidant vitamins. 
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Einleitung 
Adipositas ist ein zunehmendes Problem bei Menschen und Haustieren, z.B. in Pferden. 
Ponyrassen sind dabei besonders prädisponiert, wobei die Gründe bisher nicht abschließend 
geklärt werden konnten. Humane Adipositas geht mit einer fettigen Infiltration der Leber 
einher, die sogenannte Non-Alcoholic Fatty Liver Disease, welche zu einer hepatozellulären 
Entzündung führt. Es ist bisher nicht bekannt, ob Adipositas in Equiden auch zu hepatischen 
Veränderungen führt. Menschliche Fettleibigkeit ist zusätzlich mit systemischer Entzündung 
und gesteigertem oxidativen Stress verbunden. Das führte zu intensiven Untersuchungen von 
anti-inflammatorischen und antioxidativen Faktoren (z.B. Vitamin A - Retinol und Vitamin E 
- α-Tocopherol) in der humanen Adipositas Forschung. Viele Studien konnten ein Absinken 
von Vitamin A und Vitamin E in fettleibigen Menschen feststellen. 
Ziele 
Die vorliegende Studie sollte den Einfluss von zunehmendem Körpergewicht (KG) in Ponys 
und Pferden auf mehrere Parameter untersuchen: (1) Serum Leberenzymaktivitäten und Serum 
Gallensäuren (GS), (2) Leberfettgehalt, (3) hepatische messenger Ribonukleinsäure (mRNA) 
Level von Entzündungsmarkern und Markern des Lipidmetabolismus und (4) Serum 
Konzentrationen von Retinol und α-Tocopherol. Zusätzlich sollten Ponys und Pferde im 
Verlauf dieser Studie verglichen werden, um eventuelle Gründe für die Rasseprädisposition der 
Ponys für metabolische Störungen zu identifizieren. 
Material und Methoden 
Zehn Shetland Ponys und 9 Warmblut Pferde, die initial nicht adipös waren, wurden über 2 
Jahre mit 200% des Erhaltungsbedarfes für umsetzbare Energie gefüttert. Die Entwicklung des 
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KG, des Body Condition Scores (BCS) und des Cresty Neck Scores (CNS) wurde wöchentlich 
erfasst. Während der Fütterungsphase wurde zu 6 Zeitpunkten (ZP) Blut für die Bestimmung 
von Serum Leberenzymaktivitäten (Alkaline Phosphatase (ALP), Aspartat Aminotransferase 
(AST), Glutamat Dehydrogenase (GLDH), Gamma-Glutamyl Transferase (GGT)) und Serum 
GS entnommen und zu 7 ZP wurde Blut für die Analyse von Serum Retinol und α-Tocopherol 
gewonnen. An 3 ZP wurde durch Laparotomie Lebergewebe in Vollnarkose entnommen. Die 
Leberbiopsien wurden histologisch auf ihren Fettgehalt untersucht und mittels quantitativer 
Echtzeit Polymerase-Kettenreaktion (RT-qPCR) wurden die mRNA Level von 
Entzündungsmarkern (Nuclear Factor-κB (NF-κB), Interleukin-1β (IL-1β), IL-6, Tumor 
Nekrose Faktor α (TNFα), Differenzierungsgruppe 68 (CD68), Chemerin) und Lipid 
Metabolismus Markern (Lipoprotein Lipase (LPL), Fettsäuren Bindungsprotein 1 (FABP1) 
bestimmt. Die Daten wurden mittels statistischem Software Programm ausgewertet 
(STATISTICA, version 12, StatSoft GmbH, Hamburg, Deutschland). Nach Prüfung auf 
Normalverteilung der Daten, wurden geeignete statistische Tests angewendet mit einem 
statistischen Signifikanzniveau bei P < 0,05. Die Tierschutzkommission des Bezirks Leipzig 
genehmigte das Projekt in Übereinstimmung mit deutschen Rechtsvorschriften (Nr. TVV 
32/15). 
Ergebnisse 
Ponys und Pferde zeigten einen signifikanten Anstieg von KG (Mittelwert ± SD; Ponys: 29,9 ± 
19,4%; Pferde: 17 ± 6,74%), BCS (Median (25./75. Perzentil); Ponys: 157% (115/349); Pferde: 
142% (128/192)) und CNS (Median (25./75. Perzentil); Ponys: 165% (123/500); Pferde: 200% 
(160/225)) induziert durch die hyperkalorische Fütterung über 2 Jahre. Das ansteigende KG hat 
keine Steatosis in der Mehrheit der Equiden ausgelöst. Die mRNA Level von IL-6, TNFα, 
CD68 und IL-1β in der Leber wurden nicht beeinflusst. Die Leber mRNA Level von Chemerin 
sind signifikant angestiegen in Ponys (x-facher Anstieg: 1,89) und Pferden (x-facher Anstieg: 
2,04). Signifikante Unterschiede zwischen den Rassen hinsichtlich der Serum GLDH 
Aktivitäten, Serum GS Konzentrationen und der hepatischen mRNA LPL Level konnten 
festgestellt werden. Die Serum α-Tocopherol Konzentrationen stiegen in Ponys und Pferden 
signifikant an und korrelierten positiv mit der Vitamin E Aufnahme. Die Serum Retinol 
Konzentrationen fluktuierten während der Studie, ohne mit der Aufnahme zu korrelieren. 
Schlussfolgerungen 
Frühe Fettleibigkeit in Equiden führt nicht zwangsläufig zu einer Steatose mit hepatozellulärer 
Entzündung. Gemäß der Hypothese zeigten Ponys und Pferde allerdings unterschiedliche 
hepatische Reaktionsmuster nach KG Zunahme. Das könnte die höhere Empfänglichkeit von 
Ponys für metabolische Erkrankungen erklären. Chemerin konnte als interessanter Marker für 
die equine Adipositas Forschung identifiziert werden. Serum Konzentrationen von Retinol und 
α-Tocopherol wurden durch die KG Zunahme nicht beeinflusst. 
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The influence of body weight gain on inflammatory cytokine expressions in adipose tissue 
depots of equines 
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8.3 Individual values  
Table 1: Crude nutrients (in % of dry matter), dry matter (%) and energy content (MJ ME/kg original substance) of the used hay 
  
 
     
Time point 
Energy content Dry matter Crude ash Crude fat 
Crude 
protein 
Crude fibre NfE 
[MJ ME/kg oS] % in % of dry matter 
28.10.2015 6.27 87.8 5.45 1.58 10.1 32 50.8 
08.01.2016 6.66 91.8 3.48 0.77 14.4 31.6 49.8 
04.02.2016 6.37 89.1 8.87 1.37 7.12 29.9 52.8 
29.02.2016 5.87 89.6 8.92 0.83 7.61 32 50.7 
30.03.2016 6.1 89.9 6.19 0.81 5.63 33.8 53.6 
27.04.2016 6.7 88.7 5.12 1.41 8.87 30.8 53.8 
23.05.2016 6.24 89.5 4.57 1.4 7.09 34.7 52.3 
20.06.2016 6.96 89.8 4.71 1.51 9.29 30.3 54.2 
19.07.2016 6.45 89.9 5.3 1.58 9 32.7 51.5 
16.08.2016 6.76 90.8 5.56 1.38 8.86 30.9 53.3 
15.09.2016 6.14 91.8 5.48 1.84 9.16 35.2 48.3 
11.10.2016 4.26 89.2 6.37 1.88 9.11 43.8 38.8 
25.11.2016 6.78 92.6 5.76 1.64 7.47 32.1 53.1 
03.01.2017 5.77 86.1 3.82 1.45 7.47 36.6 50.6 
14.02.2017 6.62 91.3 4.16 2.35 7.33 34.7 51.4 
07.03.2017 6.51 88.3 3.68 2.04 8.35 33.9 52 
08.05.2017 6.08 87.6 5.41 1.56 6.93 34.3 51.8 
06.06.2017 5.63 91.7 4.62 1.98 8.23 39.1 46.1 
05.07.2017 5.76 89.6 5.68 2.23 7.64 37.1 47.3 
01.08.2017 6.39 89.5 5.67 1.91 7.61 33.3 51.5 
29.08.2017 6.5 90.5 3.94 2.72 7.81 35.6 50 
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Table 2: Crude nutrients (in % of dry matter), dry matter (%) and energy content (MJ ME/kg 
original substance) of the used concentrate 
Batches 
Energy content 
Dry 
matter 
Crude 
ash 
Crude fat 
Crude 
protein 
Crude 
fibre 
NfE1 
 [MJ ME/kg oS] [%] in % of dry matter 
1 13.3 90 7.89 14.6 13.3 10.4 53.8 
2 13.4 90 8 14.4 13.4 9.8 54.3 
3 13.1 90 7.89 14.2 13 11 53.9 
4 13.2 90 7.9 14.4 13.3 10.4 54 
5 14.8 90 7.44 17.3 14.2 6.89 54.1 
6 14.7 91.9 5.99 15.9 13.7 8.19 56.2 
1determined calculatory: NfE = DM – (crude ash + crude protein + crude fibre + crude fat) 
 
Table 3: Dry matter intake in % of body weight in ponies and horses at 2015, 2016 and 2017 
Ponies 2015 2016 2017 Horses 2015 2016 2017 
1 2.45 2.36 2.28 4 2.43 2.37 1.83 
3 2.81 2.65 2.63 6 2.42 2.25 1.9 
5 2.86 2.86 2.6 8 2.38 2.36 1.79 
7 2.61 2.46 2.37 10 2.37 2.34 1.88 
11 3.01 2.79 2.6 12 2.39 2.37 1.65 
13 2.84 2.72 2.48 14 2.33 2.24 1.8 
15 2.82 2.72 2.59 16 2.36 2.33 1.9 
17 2.73 2.64 2.5 20 2.44 2.44 2.04 
19 2.83 2.7 2.54 22 2.4 2.33 1.92 
21 2.76 2.78 2.63     
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Table 4: Energy intake (% of maintenance metabolizable energy requirements) in ponies and 
horses at 4 time periods during the study 
Ponies 
05.01.2016-
22.05.2016 
23.05.2016-
09.10.2016 
25.12.2016-
05.06.2017 
06.06.2017-
08.10.201 
1 200 200 200 200 
3 200 200 200 200 
5 200 200 200 200 
7 200 200 200 200 
11 199 200 200 200 
13 200 200 200 200 
15 200 200 200 200 
17 200 200 200 200 
19 199 200 200 200 
21 200 200 200 200 
Horses 
    
4 199 195 174 162 
6 199 200 185 181 
8 196 195 183 157 
10 200 194 178 176 
12 199 192 165 156 
14 200 198 176 170 
16 196 190 176 174 
20 198 199 184 190 
22 200 198 182 173 
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Table 5: Body weight, BCS and CNS of all equines at the three time points where the CGIT 
was conducted 
 CGIT 2015 CGIT 2016 CGIT 2017 
Ponies BW (kg) BCS CNS BW (kg) BCS CNS BW (kg) BCS CNS 
1 186 3.15 2.5 220 4.1 3 226 4.75 3.75 
3 96 1.15 0.75 134 3.6 2.5 142 4.15 4 
5 99 2.8 2.5 121 3.6 2.5 132 3.9 3.5 
7 145 2.5 2.5 183 3.75 4 178 4.1 4.5 
11 108 3.4 3 121 3.4 2.75 130 3.65 3.25 
13 95 0.65 0.5 134 3.2 2.5 158 3.75 3.25 
15 120 4 3 126 3.7 2.75 132 4.15 3.5 
17 119 1.2 1 146 3.7 3.5 137 3.75 4 
19 95 0.75 0.25 134 3.25 2.25 144 3.7 3 
21 121 3.65 3 131 3.5 3 132 3.5 3.5 
Horses 
         
4 530 1.15 0.75 644 3.25 2 640 3.35 2.75 
6 596 2.5 2 754 3.8 3 780 4.8 4.5 
8 650 2.65 1.75 710 3.5 2.75 702 3.75 3.5 
10 600 2.05 2 688 3.5 3.25 678 3.65 4 
12 585 3.35 2 690 3.6 2.75 696 3.85 3 
14 650 2.9 2.25 766 3.85 3.25 752 3.8 3.75 
16 665 3.3 2.75 730 3.6 2.75 732 3.75 3.5 
20 570 1.6 1.5 666 3.1 2.75 680 3.5 3.5 
22 570 3.2 2.5 654 3.6 3 662 4.1 4 
Values of BCS and CNS were calculated as mean of two independent evaluators 
Appendix 
 
85 
 
Table 6a: Plasma glucose (mmol/L), serum insulin (µU/mL), serum triglycerides (mmol/L) and serum non-esterified free fatty acids (µmol/L) in ponies 
and horses at 2015, 2016 and 2017 
Ponies 
Glucose 
mmol/L 
Insulin 
µU/mL 
Triglycerides 
mmol/L 
Non-esterified free fatty 
acids 
µmol/L 
2015 2016 2017 2015 2016 2017 2015 2016 2017 2015 2016 2017 
1 3.49 3.83 4.1 5.25 6.46 9.99 0.34 0.28 0.3 60 334 277 
3 3.37 3.15 4.17 6.16 5.9 12.2 0.47 0.24 0.26 111 27 348 
5 3.1 4.05 5.45 5.84 8.19 16.2 0.71 0.26 0.51 58 210 166 
7 3.43 3.87 6.26 3.62 7.43 55.2 0.67 0.43 0.79 77 117 332 
11 4.01 3.73 3.37 3.7 5.57 10.6 0.32 0.32 0.2 422 40 107 
13 3.67 4.41 4.05 2.8 5.5 10.6 0.39 0.14 0.19 15 376 567 
15 5 4.57 3.73 4.68 24 5.47 0.55 0.61 0.38 137 60 488 
17 2.57 3.91 4.16 2.96 5.09 6.51 0.27 0.24 0.68 48 257 425 
19 3.28 3.91 4.32 2.34 4.89 6.86 0.33 0.36 0.39 81 120 444 
21 3.37 3.86 3.86 5.3 6.23 5.11 0.82 1.21 0.49 183 539 364 
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Table 6b: Continuation of Table 6a 
Horses 
Glucose 
mmol/L 
Insulin 
µU/mL 
Triglycerides 
mmol/L 
Non-esterified free fatty 
acids 
µmol/L 
2015 2016 2017 2015 2016 2017 2015 2016 2017 2015 2016 2017 
4 3.93 4.35 4.24 8.02 10.7 25.2 0.17 0.14 0.35 366 109 387 
6 3.82 4.61 4.94 5.66 16.4 37.9 0.26 0.21 0.45 110 152 201 
8 4.19 4.71 4.61 5.97 10.4 9.63 0.48 0.26 0.38 488 243 198 
10 4.13 4.83 3.96 5.9 7.95 8.44 0.21 0.24 0.34 45 64 192 
12 4.31 4.5 4.34 4.92 6.7 12.3 0.29 0.22 0.27 1260 327 148 
14 3.83 4.25 3.85 5.14 9.75 8.94 0.24 0.28 0.24 342 262 363 
16 4.11 4.46 4.07 4.73 6.82 17.3 0.28 0.3 0.26 29 260 170 
20 4 4.21 4.26 12.4 11.3 7.50 0.24 0.22 0.28 282 295 257 
22 4.41 4.79 5.31 5.66 8.06 8.27 0.24 0.28 0.18 113 185 309 
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Table 7: Serum Amyloid A concentrations (µg/mL) in ponies and horses at 2015, 2016 and 
2017 
Ponies 2015 2016 2017 
1 0.4 0.1 0.1 
3 0.1 0.1 0.1 
5 0.1 0.1 0.1 
7 0.1 0.6 0.1 
11 0.9 0.1 0.1 
13 0.1 0.1 340 
15 0.1 0.1 0.1 
17 0.1 0.6 0.1 
19 1.5 0.4 0.1 
21 0.1 187 0.1 
Horses 
   
4 0.1 0.1 0.1 
6 0.1 0.1 0.1 
8 0.1 0.1 0.1 
10 0.1 0.1 3.2 
12 0.1 0.1 0.1 
14 0.1 0.1 0.1 
16 0.1 0.1 0.1 
20 0.1 0.5 0.1 
22 0.1 0.1 0.1 
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Table 8a: Serum ALP (U/L), GLDH (U/L) and AST (U/L) in ponies and horses at 6 time points during the study 
 
  
Ponies 
ALP 
(U/L) 
GLDH 
(U/L) 
AST 
(U/L) 
t0 t1 t2 t3 t4 t5 t0 t1 t2 t3 t4 t5 t0 t1 t2 t3 t4 t5 
1 102 99 82 80 110 80 7.5 12.2 10.3 8.4 11 7.7 445 439 430 294 304 267 
3 148 135 112 124 164 112 4.1 8.8 10.4 4.5 5.1 4 340 389 381 362 269 255 
5 238 170 143 173 196 171 3 18 4 6 9.6 4.1 512 489 434 442 456 314 
7 225 123 105 138 161 139 3 7.7 27 27.9 12.6 6.4 270 380 366 387 356 343 
11 340 165 96 113 125 79 20.3 47.5 23.9 60.7 140 31.6 337 581 505 532 587 446 
13 179 171 151 149 131 124 2.6 54.2 27.2 24.5 21.4 21.2 332 518 360 411 524 423 
15 154 151 124 116 146 101 2.4 7.6 1.8 12.1 4.4 4.4 283 446 326 392 379 336 
17 134 131 122 113 151 836 7.3 26.1 62.1 5.8 14.8 37.8 373 497 466 406 397 437 
19 230 164 123 138 158 135 7.8 33.9 10.2 27.1 27.8 24.1 255 570 421 460 435 428 
21 293 237 200 377 591 199 12.4 21.5 11 255 311 76.4 411 448 389 698 629 478 
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Table 8b: Continuation of Table 8a 
 
 
  
Horses 
ALP 
(U/L) 
GLDH 
(U/L) 
AST 
(U/L) 
t0 t1 t2 t3 t4 t5 t0 t1 t2 t3 t4 t5 t0 t1 t2 t3 t4 t5 
4 130 96 92 93 108 81 2 3.5 3.4 2.4 5.9 1 278 322 306 309 325 247 
6 167 141 110 129 154 128 35.8 5.3 2.1 1.7 3.9 13.4 605 404 317 355 295 445 
8 127 98 83 94 107 89 11.6 4.5 2.2 2.1 5 3 399 321 284 257 287 269 
10 135 156 114 127 136 103 2.9 2.4 2 1.6 1.7  376 416 336 359 299 278 
12 170 155 184 143 146 141 2.2 4.1 4.3 3.2 3.9 7.3 307 359 337 320 303 274 
14 184 96 87 113 123 112 1.9 5.2 7.6 4 2.5 8.7 305 352 312 270 262 291 
16 109 116 117 120 116 99 1.9 3.5 2.2 2.3 2.9 2.7 307 317 284 310 292 300 
20 156 146 141 128 141 149 2 2.8 21.9 2.8 12.7 126 349 396 435 316 503 770 
22 88 77 65 76 90 70 1.5 2.9 1.9 2.6 2.8 1.3 322 339 308 322 313 286 
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Table 9: Serum GGT (U/L) activities and serum BA (µmol/L) concentrations in ponies and horses 
at 6 time points during the study 
 
Ponies 
GGT 
(U/L) 
BA 
(µmol/L) 
t0 t1 t2 t3 t4 t5 t0 t1 t2 t3 t4 t5 
1 64.4 28.9 22.7 18.5 25.6 25.7 5.2 8.9 6.1 14.7 15 10.1 
3 28.5 25.6 14.4 14.4 16.2 15.9 6 10.1 6.2 6.9 5.4 7.7 
5 213 45.5 14.9 17 29.1 20.3 2.7 9.7 6 4.9 6.7 5.6 
7 57 28.6 28.1 43.8 91.9 73.1 3.7 9.2 4.1 11 4 5.6 
11 122 25.4 29.7 28.6 50.4 29.8 6 8.9 5.1 8.9 9.4 8.7 
13 63 22.4 13.8 16.9 33.3 21.1 7.2 18.5 23.3 23.8 22.4 18.6 
15 36 24.2 12.3 13.6 19.6 15.1 1.7 5.6 2.9 12 8 8.3 
17 68 52.4 26.4 17.9 22.5 155 5.6 13.5 17.3 10.4 13 33.7 
19 45.3 30.5 14.3 17.4 19.4 23.9 6.5 13.4 2.8 16.1 21.1 14.9 
21 265 19.5 18.4 199 363 170 5.8 11.5 13.3 17.4 25.3 10.9 
Horses 
            
4 10.3 17.8 17.1 17.3 20.7 15.5 3.2 6 12.4 5.4 9.4 3.8 
6 103 33.9 19.3 18.4 19.2 52.9 8.1 6.4 4.6 2.4 5 5 
8 39.1 16.4 10.8 12.5 13.9 14.8 2 5.9 8.8 7 8.4 5 
10 26.1 16.4 11.6 12.5 11.2 11.7 2.1 2.4 2.3 2.5 3.5 2.7 
12 24.6 22.2 44.2 13.7 15.3 13.8 3 5.4 9.4 4.1 4.8 6.8 
14 31.9 34.4 26.3 33.8 32.5 53.6 3.2 4.8 6.3 4.5 4.3 4.4 
16 16.8 20.6 12.9 12.1 12 14.9 2.9 7.2 5.7 9.4 5.5 5.9 
20 128 26.3 15.1 13.2 32.5 57.7 6.1 3.3 10.4 3.9 7.8 11.5 
22 6.6 12.8 9.6 9.6 17.6 12.7 8.3 7.3 7.3 7.7 6 13 
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Table 10: Staging of steatosis in liver tissue samples of ponies and horses at 2015 and 2017 
Ponies 2015 2017 
1 0 0 
3 1 1 
5 0 2 
7 0 1 
11 1 0 
13 0 0 
15 0 0 
17 0 3 
19 0 0 
21 0 0 
Horses 
  
4 0 0 
6 0 0 
8 0 0 
10 0 1 
12 0 0 
14 1 0 
16 0  
20 1 0 
22 1 0 
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Table 11: x-fold mRNA levels of CD68, IL-1β, IL-6 and Nf-κB normalized to the geometric 
means of the three reference genes 18S, HPRT1 and RPL32 in ponies and horses at 2015,2016 
and 2017 
Ponies 
CD68 IL-1β IL-6 Nf-κB 
2015 2016 2017 2015 2016 2017 2015 2016 2017 2015 2016 2017 
1 0.52 0.45 0.4 0.73 0.85 2.04 0.2 0.26 1.99 0.81 0.52 0.96 
3 1.04 0.57 0.51 1.55 0.35 0.39 1.51 0.2 0.45 1.21 0.57 0.53 
5 0.79 0.42 0.71 1.41 1.03 1.2 0.89 0.63 0.8 1.86 0.59 0.65 
7 0.7 1.35 0.62 0.86 0.37 0.7 0.25 0.27 0.38 0.73 0.76 0.47 
11 1.92 1.25 0.69 0.42 1.36 1.04 0.29 0.85 0.09 0.88 0.94 0.58 
13 0.64 0.83 0.8 0.79 0.42 0.74 0.53 0.35 0.77 1 0.7 0.63 
15 0.56 0.7 0.77 5.05 0.94 0.57 4.81 0.3 0.82 0.82 0.76 0.55 
17 0.68 0.86 0.86 0.46 0.96 0.66 0.28 0.25 0.62 0.67 0.72 0.91 
19 0.75 0.18 0.56 0.41 0.48 0.65 0.16 0.2 0.62 0.78 0.88 0.62 
21 0.84 1.37 0.49 0.78 0.53 0.62 0.25 0.23 0.27 0.76 0.66 0.59 
Horses 
            
4 0.5 0.52 0.52 0.52 0.52 0.77 0.29 0.32 0.56 0.56 0.67 0.54 
6 2.04 0.53 0.6 0.49 0.44 0.98 0.24 0.15 0.46 1.17 0.61 0.49 
8 0.41 0.36 0.4 0.63 0.51 0.56 0.3 0.23 0.44 0.49 0.7 0.42 
10 0.56 0.86 1.18 0.49 0.32 0.58 0.19 0.4 0.53 0.62 0.99 0.99 
12 0.37 0.44 0.38 0.64 0.79 0.55 0.27 0.82 0.26 1.07 0.85 0.47 
14 0.46 0.59 0.49 1.46 0.54 0.34 1.21 0.32 0.14 0.87 0.74 0.39 
16 0.42 0.54 0.52 0.4 0.48 0.4 0.1 0.22 0.26 0.66 0.76 0.45 
20 1.01 0.52 0.46 0.23 0.37 0.44 0.33 0.13 0.32 0.75 0.59 0.4 
22 0.58 0.45 0.2 0.79 0.7 0.16 0.44 0.41 0.88 0.49 0.46 0.46 
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Table 12: x-fold mRNA levels of TNFα, Chemerin, FABP1 and LPL normalized to the 
geometric means of the three reference genes 18S, HPRT1 and RPL32 in ponies and horses at 
2015,2016 and 2017 
Ponies 
TNFα Chemerin FABP1 LPL 
2015 2016 2017 2015 2016 2017 2015 2016 2017 2015 2016 2017 
1 0.4 0.37 2.1 0.47 0.63 1.33 0.96 0.18 0.2 0.4 0.35 0.48 
3 1.39 0.23 0.7 0.55 0.72 1.31 0.69 0.41 0.37 1.04 0.26 0.61 
5 0.72 0.6 1.22 0.62 0.76 1.22 0.62 0.52 0.34 0.54 0.3 3.8 
7 0.82 0.73 0.41 0.67 0.8 1.19 0.53 0.67 0.85 0.3 0.41 0.43 
11 0.49 1.13 0.47 0.83 0.69 0.83 0.73 0.39 0.74 1.64 1.05 0.54 
13 0.52 0.81 1.11 0.76 0.76 0.99 0.76 0.35 0.61 1.57 0.89 1.45 
15 4.13 0.66 1.21 0.49 0.71 1.45 0.49 0.62 0.78 0.28 0.21 1.48 
17 0.44 0.4 0.66 0.55 0.75 1.36 0.73 0.62 1.71 1.57 1.26 2.07 
19 0.37 0.73 0.75 0.66 0.57 0.87 0.73 0.39 0.75 0.32 0.85 0.45 
21 0.76 1.03 0.7 0.86 0.44 0.52 0.46 0.34 0.56 0.46 2.5 1.08 
Horses 
            
4 0.47 0.47 0.64 0.55 0.68 1.27 0.75 0.51 0.7 0.5 0.36 0.76 
6 0.46 0.31 0.94 0.61 0.78 1.23 0.69 0.66 0.71 0.45 0.43 0.44 
8 0.39 0.21 0.49 0.66 0.73 1.27 0.73 0.67 1.01 0.2 0.12 0.13 
10 0.37 0.77 0.72 0.58 0.52 1.11 0.83 0.52 1.21 0.24 0.61 0.6 
12 0.45 0.91 0.77 0.46 0.51 0.91 0.38 0.42 0.5 0.4 0.24 0.24 
14 1.19 0.75 0.38 0.55 0.7 1.12 0.42 0.28 0.44 0.22 0.59 0.35 
16 0.31 0.38 0.32 0.59 0.71 1.26 0.41 0.49 0.19 0.41 0.18 0.34 
20 0.34 0.32 0.59 0.74 0.58 1.2 1.0 0.56 0.93 1.05 0.18 0.3 
22 0.53 0.58 1.5 0.67 0.54 0.79 1.03 0.68 0.94 0.53 0.21 0.22 
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Table 13a: Serum α-tocopherol (µg/mL), retinol (µM) and RBP4 (µM) in ponies and horses at 7 timepoints during the study 
 
  
Ponies 
α-tocopherol 
(µg/mL) 
 
Retinol 
(µM) 
RBP4 
(µM) 
 
t0 t1 t2 t3 t4 t5 t6 t0 t1 t2 t3 t4 t5 t6 t0 t1 t2 t3 t4 t5 t6 
1 2.75 2.41 2.9 4.34 11.7 5.19 9.1 0.41 0.43 0.37 0.33 0.41 0.3 0.35 0.31 0.34 0.33 0.33 0.16 0.12 0.21 
3 1.87 2.38 1.51 2.57 5.43 4.71 5.72 0.13 0.32 0.3 0.33 0.38 0.41 0.42 0.18 0.24 0.32 0.44 0.23 0.15 0.12 
5 2.19 1.33 2.3 5.9 10.3 2.89 11.2 0.27 0.43 0.26 0.26 0.31 0.39 0.29 0.23 0.28 0.5 0.55 0.26 0.14 0.16 
7 3.69 1.76 1.11 1.44 2.78 6.96 3.87 0.26 0.41 0.41 0.35 0.37 0.25 0.41 0.26 0.5 0.57 0.19 0.2 0.12 0.26 
11 3.44 3.77 2.94 3.95 5.7 2.08 6.24 0.27 0.29 0.31 0.25 0.28 0.33 0.28 0.31 0.22 0.73 0.35 0.24 0.19 0.19 
13 1.45 1.16 1.54 3.1 4.84 3.5 4.16 0.25 0.33 0.39 0.33 0.43 0.3 0.49 0.41 0.42 0.49 0.22 0.25 0.17 0.24 
15 2.5 1.82 1.5 4.27 4.81 4.33 6.38 0.38 0.44 0.39 0.28 0.37 0.27 0.36 0.31 0.4 0.42 0.27 0.2 0.18 0.33 
17 2.18 1.38 1.62 4.64 6.11 6.08 8.39 0.39 0.45 0.29 0.31 0.33 0.21 0.47 0.44 0.3 0.33 0.27 0.18 0.18 0.13 
19 1.64 1.32 1.42 2.69 4.84 5.19 6.34 0.22 0.31 0.3 0.26 0.25 0.2 0.26 0.31 0.39 0.37 0.17 0.18 0.19 0.23 
21 1.79 3.31 2.68 6.22 7.65 6.98 6.81 0.51 0.38 0.42 0.28 0.48 0.43 0.43 0.22 0.48 0.28 0.39 0.24 0.56 0.47 
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Table 13b: Continuation of Table 13a 
 
 
Horses 
α-tocopherol 
(µg/mL) 
 
Retinol 
(µM) 
RBP4 
(µM) 
 
t0 t1 t2 t3 t4 t5 t6 t0 t1 t2 t3 t4 t5 t6 t0 t1 t2 t3 t4 t5 t6 
4 2.52 1.69 1.43 2.16 3.42 6.08 1.64 0.33 0.43 0.33 0.35 0.44 0.39 0.41 0.21 0.29 0.15 0.6 0.3 0.16 0.24 
6 2.22 1.54 2.17 2.5 3.64 2.68 4.4 0.56 0.46 0.27 0.46 0.41 0.43 0.71 0.41 0.41 0.64 0.28 0.27 0.12 0.23 
8 3.16 2.43 3.29 4.39 5.58 3.16 6.31 0.44 0.43 0.43 0.34 0.41 0.41 0.42 0.33 0.75 0.47 0.21 0.25 0.17 0.22 
10 0.73 1 1.57 3.39 5.1 5.04 5.59 0.38 0.53 0.44 0.4 0.4 0.34 0.47 0.27 0.25 0.59 0.34 0.15 0.28 0.26 
12 1.98 1.44 2.04 4.38 5.81 8.3 5.92 0.27 0.34 0.32 0.31 0.3 0.32 0.34 0.17 0.17 0.51 0.21 0.22 0.32 0.31 
14 1.98 1.21 1.47 2.54 3.3 2.32 4.37 0.5 0.4 0.39 0.39 0.36 0.31 0.44 0.31 0.34 0.32 0.21 0.19 0.15 0.24 
16 1.47 1.61 2.22 3.02 3.57 3.38 4.51 0.38 0.45 0.38 0.35 0.44 0.38 0.47 0.39 0.38 0.32 0.22 0.34 0.2 0.26 
20 1.47 0.79 1.62 2.94 3.75 2.95 6.24 0.38 0.4 0.28 0.26 0.33 0.28 0.43 0.34 0.33 0.44 0.33 0.25 0.2 0.36 
22 0.52 0.58 1.15 2.44 3.33 3.1 4.69 0.37 0.28 0.26 0.29 0.32 0.24 0.33 0.36 0.34 0.55 0.37 0.23 0.21 0.24 
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